研究・実績 > 業績
業績
研究業績目録（谷内一彦）
原著欧文（Reprintが必要な場合には連絡くださいyanai@med.tohoku.ac.jp）
| 1. | Naganuma F‚ Girgin B‚ Agu ABS‚ Hirano K‚ Nakamura T‚ Yanai K‚ Vetrivelan R‚ Mochizuki T‚ Yanagisawa M‚ Yoshikawa T. Pharmacological inhibition of histamine N-methyltransferase extends wakefulness and suppresses cataplexy in a mouse model of narcolepsy. Sleep. 2025 Jan 13;48(1):zsae244. |
|---|---|
| 2. | Kobayashi Y‚ Hiraoka K‚ Itabashi R‚ Saito T‚ Kawabata Y‚ Yazawa Y‚ Funaki Y‚ Furumoto S‚ Okamura N‚ Furukawa K‚ Ishiki A‚ Arai H‚ Yanai K‚ Tashiro M‚ Sekijima Y. Amyloid accumulation in cases of suspected comorbid cerebral amyloid angiopathy and isolated cortical venous thrombosis. J Neurol Sci. 2024 Feb 15;457:122892. |
| 3. | Yoshida Y‚ Yokoi T‚ Hara K‚ Watanabe H‚ Yamaguchi H‚ Bagarinao E‚ Masuda M‚ Kato T‚ Ogura A‚ Ohdake R‚ Kawabata K‚ Katsuno M‚ Kato K‚ Naganawa S‚ Okamura N‚ Yanai K‚ Sobue G. Pattern of THK 5351 retention in normal aging involves core regions of resting state networks associated with higher cognitive function. Nagoya J Med Sci. 2023 Nov;85(4):758-771. |
| 4. | Harada R‚ Lerdsirisuk P‚ Shimizu Y‚ Yokoyama Y‚ Du Y‚ Kudo K‚ Ezura M‚ Ishikawa Y‚ Iwata R‚ Shidahara M‚ Ishiki A‚ Kikuchi A‚ Hatano Y‚ Ishihara T‚ Onodera O‚ Iwasaki Y‚ Yoshida M‚ Taki Y‚ Arai H‚ Kudo Y‚ Yanai K‚ Furumoto S‚ Okamura N. Preclinical Characterization of the Tau PET Tracer [18F]SNFT-1: Comparison of Tau PET Tracers. J Nucl Med. 2023 Sep;64(9):1495-1501. |
| 5. | Morito T‚ Harada R‚ Iwata R‚ Ishikawa Y‚ Okamura N‚ Kudo Y‚ Furumoto S‚ Yanai K‚ Tashiro M. Evaluation of 18F labeled glial fibrillary acidic protein binding nanobody and its brain shuttle peptide fusion proteins using a neuroinflammation rat model. PLoS One. 2023 Jun 14;18(6):e0287047. |
| 6. | Sakurai K‚ Nihashi T‚ Kimura Y‚ Iwata K‚ Ikenuma H‚ Arahata Y‚ Okamura N‚ Yanai K‚ Akagi A‚ Ito K‚ Kato T‚ Nakamura A‚ Group MS. Age-related increase of monoamine oxidase B in amyloid-negative cognitively unimpaired elderly subjects. Ann Nucl Med. 2022 Aug;36(8):777-784. |
| 7. | Otsuka R‚ Naganuma F‚ Nakamura T‚ Miwa H‚ Nakayama-Naono R‚ Matsuzawa T‚ Komatsu Y‚ Sato Y‚ Takahashi Y‚ Tatsuoka-Kitano H‚ Yanai K‚ Yoshikawa T. Contribution of astrocytic histamine N-methyltransferase to histamine clearance and brain function in mice. Neuropharmacology. 2022 Jul 1;212:109065. |
| 8. | Nakamura T‚ Naganuma F‚ Kudomi U‚ Roh S‚ Yanai K‚ Yoshikawa T. Oral histidine intake improves working memory through the activation of histaminergic nervous system in mice. Biochem Biophys Res Commun. 2022 Jun 18;609:141-148. |
| 9. | Villemagne VL‚ Harada R‚ Dore V‚ Furumoto S‚ Mulligan R‚ Kudo Y‚ Burnham S‚ Krishnadas N‚ Bozinovski S‚ Huang K‚ Lopresti BJ‚ Yanai K‚ Rowe CC‚ Okamura N. First-in-human evaluation of 18F-SMBT-1‚ a novel 18F-labeled MAO-B PET tracer for imaging reactive astrogliosis. J Nucl Med. J Nucl Med. 2022 Oct;63(10):1551-1559. |
| 10. | Villemagne VL‚ Harada R‚ Dore V‚ Furumoto S‚ Mulligan R‚ Kudo Y‚ Burnham S‚ Krishnadas N‚ Bourgeat P‚ Xia Y‚ Laws S‚ Bozinovski S‚ Huang K‚ Ikonomovic MD‚ Fripp J‚ Yanai K‚ Okamura N‚ Rowe CC. Assessing reactive astrogliosis with 18F-SMBT-1 across the Alzheimer's disease spectrum. J Nucl Med. 2022 Oct;63(10):1560-1569. |
| 11. | Harada R‚ Shimizu Y‚ Du Y‚ Ishikawa Y‚ Iwata R‚ Kudo Y‚ Yanai K‚ Okamura N‚ Furumoto S.The Role of Chirality of [18F]SMBT-1 in Imaging of Monoamine Oxidase-B. ACS Chem Neurosci. 2022 Feb 2;13(3):322-329 |
| 12. | Ezura M‚ Kikuchi A‚ Okamura N‚ Ishiki A‚ Hasegawa T‚ Harada R‚ Watanuki S‚ Funaki Y‚ Hiraoka K‚ Baba T‚ Sugeno N‚ Yoshida S‚ Kobayashi J‚ Kobayashi M‚ Tano O‚ Ishiyama S‚ Nakamura T‚ Nakashima I‚ Mugikura S‚ Iwata R‚ Taki Y‚ Furukawa K‚ Arai H‚ Furumoto S‚ Tashiro M‚ Yanai K‚ Kudo Y‚ Takeda A‚ Aoki M.18F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies.Front Aging Neurosci. 2021 Nov 29;13:761010. |
| 13. | Nihashi T‚ Sakurai K‚ Kato T‚ Iwata K‚ Kimura Y‚ Ikenuma H‚ Yamaoka A‚ Takeda A‚ Arahata Y‚ Washimi Y‚ Suzuki K‚ Bundo M‚ Sakurai T‚ Okamura N‚ Yanai K‚ Ito K‚ Nakamura A; MULNIAD Study Group. Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum. J Alzheimers Dis. 2022;85(1):223-234. |
| 14. | Naganuma F‚ Nakamura T‚ Kuroyanagi H‚ Tanaka M‚ Yoshikawa T‚ Yanai K‚ Okamura N. Chemogenetic modulation of histaminergic neurons in the tuberomamillary nucleus alters territorial aggression and wakefulness. Sci Rep. 2021 Sep 9;11(1):17935 |
| 15. | Matsuzawa T‚ Morita M‚ Shimane A‚ Otsuka R‚ Mei Y‚ Irie F‚ Yamaguchi Y‚ Yanai K‚ Yoshikawa T. Heparan sulfate promotes differentiation of white adipocytes to maintain insulin sensitivity and glucose homeostasis. J Biol Chem. 2021 Jul 24;297(3):101006. |
| 16. | Morito T‚ Harada R‚ Iwata R‚ Du Y‚ Okamura N‚ Kudo Y‚ Yanai K. Synthesis and pharmacokinetic characterisation of a fluorine-18 labelled brain shuttle peptide fusion dimeric affibody. Sci Rep. 2021 Jan 28;11(1):2588. |
| 17. | Hiraoka K‚ Inada H‚ Yanai K‚ Osumi N. Bone Morphogenetic Proteins Inhibit Ciliogenesis of Ependymal Cells in Vitro. Tohoku J Exp Med. 2020 Nov;252(3):199-208. |
| 18. | Iwata R‚ Terasaki K‚ Ishikawa Y‚ Harada R‚ Furumoto S‚ Yanai K‚ Pascali C. A concentration-based microscale method for 18F-nucleophilic substitutions and its testing on the one-pot radiosynthesis of [18F]FET and [18F]fallypride. Appl Radiat Isot. 2020 Aug 3;166:109361. |
| 19. | Yokoyama M‚ Matsuzawa T‚ Yoshikawa T‚ Nunomiya A‚ Yamaguchi Y‚ Yanai K. Heparan sulfate controls skeletal muscle differentiation and motor functions. Biochim Biophys Acta Gen Subj. 2020 Aug 15;1864(12):129707. |
| 20. | Harada R‚ Hayakawa Y‚ Ezura M‚ Lerdsirisuk P‚ Du Y‚ Ishikawa Y‚ Iwata R‚ Shidahara M‚ Ishiki A‚ Kikuchi A‚ Arai H‚ Kudo Y‚ Yanai K‚ Furumoto S‚ Okamura N. 18F-SMBT-1: A Selective and Reversible Positron-Emission Tomography Tracer for Monoamine Oxidase-B Imaging. J Nucl Med. 2021 Feb;62(2):253-258. |
| 21. | Yamada Y‚ Yoshikawa T‚ Naganuma F‚ Kikkawa T‚ Osumi N‚ Yanai K. Chronic Brain Histamine Depletion in Adult Mice Induced Depression-Like Behaviours and Impaired Sleep-Wake Cycle. Neuropharmacology 2020 Jun 6;175:108179. |
| 22. | Kárpáti A‚ Yoshikawa T‚ Naganuma F‚ Matsuzawa T‚ Kitano H‚ Yamada Y‚ Yokoyama M‚ Futatsugi A‚ Mikoshiba K‚ Yanai K. Histamine H1 receptor on astrocytes and neurons controls distinct aspects of mouse behaviour. Sci Rep. 2019 Nov 11;9(1):16451. |
| 23. | Nakamura T‚ Hiraoka K‚ Harada R‚ Matsuzawa T‚ Ishikawa Y‚ Funaki Y‚ Yoshikawa T‚ Tashiro M‚ Yanai K‚ Okamura N. Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine. Pharmacol Res Perspect. 2019 Jul 12;7(4):e00499. |
| 24. | Ezura M‚ Kikuchi A‚ Ishiki A‚ Okamura N‚ Hasegawa T‚ Harada R‚ Watanuki S‚ Funaki Y‚ Hiraoka K‚ Baba T‚ Sugeno N‚ Oshima R‚ Yoshida S‚ Kobayashi J‚ Kobayashi M‚ Tano O‚ Nakashima I‚ Mugikura S‚ Iwata R‚ Taki Y‚ Furukawa K‚ Arai H‚ Furumoto S‚ Tashiro M‚ Yanai K‚ Kudo Y‚ Takeda A‚ Aoki M. Longitudinal changes in 18 F-THK5351 PET in corticobasal syndrome. Eur J Neurol. 2019 Apr 13. doi: 10.1111/ene.13966. |
| 25. | Kamei M‚ Otani Y‚ Hayashi H‚ Nakamura T‚ Yanai K‚ Furuta K‚ Tanaka S. Suppression of IFN-γ Production in Murine Splenocytes by Histamine Receptor Antagonists. Int J Mol Sci. 2018 Dec 17;19(12). |
| 26. | Yokoi T‚ Watanabe H‚ Yamaguchi H‚ Bagarinao E‚ Masuda M‚ Imai K‚ Ogura A‚ Ohdake R‚ Kawabata K‚ Hara K‚ Riku Y‚ Ishigaki S‚ Katsuno M‚ Miyao S‚ Kato K‚ Naganawa S‚ Harada R‚ Okamura N‚ Yanai K‚ Yoshida M‚ Sobue G. Involvement of the Precuneus/Posterior Cingulate Cortex Is Significant for the Development of Alzheimer's Disease: A PET (THK5351‚ PiB) and Resting fMRI Study. Front Aging Neurosci. 2018 Oct 5;10:304. |
| 27. | Yanai A‚ Harada R‚ Iwata R‚ Yoshikawa T‚ Ishikawa Y‚ Furumoto S‚ Ishida T‚ Yanai K. Site-Specific Labeling of F-18 Proteins Using a Supplemented Cell-Free Protein Synthesis System and O-2-[18F]Fluoroethyl-L-Tyrosine: [18F]FET-HER2 Affibody Molecule. Mol Imaging Biol. 2019 Jun;21(3):529-537. |
| 28. | Sedjahtera A‚ Gunawan L‚ Bray L‚ Hung LW‚ Parsons J‚ Okamura N‚ Villemagne VL‚ Yanai K‚ Liu XM‚ Chan J‚ Bush AI‚ Finkelstein DI‚ Barnham KJ‚ Cherny RA‚ Adlard PA. Targeting metals rescues the phenotype in an animal model of tauopathy. Metallomics. 2018 Sep 19;10(9):1339-1347. |
| 29. | Kuramasu A‚ Wakabayashi M‚ Inui M‚ Yanai K. Distinct Roles of Small GTPases Rac1 and Rac2 in Histamine H4 Receptor-Mediated Chemotaxis of Mast Cells. J Pharmacol Exp Ther. 2018 Oct;367(1):9-19. |
| 30. | Ishiki A‚ Harada R‚ Kai H‚ Sato N‚ Totsune T‚ Tomita N‚ Watanuki S‚ Hiraoka K‚ Ishikawa Y‚ Funaki Y‚ Iwata R‚ Furumoto S‚ Tashiro M‚ Sasano H‚ Kitamoto T‚ Kudo Y‚ Yanai K‚ Furukawa K‚ Okamura N‚ Arai H. Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy. Acta Neuropathol Commun. 2018 Jun 29;6(1):53. |
| 31. | Kárpáti A‚ Yoshikawa T‚ Nakamura T‚ Iida T‚ Matsuzawa T‚ Kitano H‚ Harada R‚ Yanai K. Histamine elicits glutamate release from cultured astrocytes. J Pharmacol Sci. 2018 Jun;137(2):122-128. |
| 32. | Eguchi K‚ Shindo T‚ Ito K‚ Ogata T‚ Kurosawa R‚ Kagaya Y‚ Monma Y‚ Ichijo S‚ Kasukabe S‚ Miyata S‚ Yoshikawa T‚ Yanai K‚ Taki H‚ Kanai H‚ Osumi N‚ Shimokawa H. Whole-brain low-intensity pulsed ultrasound therapy markedly improves cognitive dysfunctions in mouse models of dementia - Crucial roles of endothelial nitric oxide synthase. Brain Stimul. 2018 May 22 in press [Epub ahead of print] |
| 33. | Yanai A‚ Itoh M‚ Hirakawa H‚ Yanai K‚ Tashiro M‚ Harada R‚ Yoshikawa A‚ Yamamoto S‚ Ohuchi N‚ Ishida T. Newly-Developed Positron Emission Mammography (PEM) Device for the Detection of Small Breast Cancer. Tohoku J Exp Med. 2018 May;245(1):13-19. |
| 34. | Matsuzawa T‚ Yoshikawa T‚ Iida T‚ Kárpáti A‚ Kitano H‚ Harada R‚ Nakamura T‚ Sugawara A‚ Yamaguchi Y‚ Yanai K. Heparan sulfate in pancreatic β-cells contributes to normal glucose homeostasis by regulating insulin secretion. Biochem Biophys Res Commun. 2018 May 15;499(3):688-695 |
| 35. | Kikuchi A‚ Nasir FBM‚ Inami A‚ Mohsen A‚ Watanuki S‚ Miyake M‚ Takeda K‚ Koike D‚ Ito T‚ Sasakawa J‚ Matsuda R‚ Hiraoka K‚ Maurer M‚ Yanai K‚ Watabe H‚ Tashiro M. Effects of levocetirizine and diphenhydramine on regional glucose metabolic changes and hemodynamic responses in the human prefrontal cortex during cognitive tasks. Hum Psychopharmacol. 2018 Mar;33(2):e2655. |
| 36. | Iwata R‚ Pascali C‚ Terasaki K‚ Ishikawa Y‚ Furumoto S‚ Yanai K. Practical microscale one-pot radiosynthesis of 18 F-labeled probes. J Labelled Comp Radiopharm.2018 Jun 15;61(7):540-549. |
| 37. | Naganuma F‚ Nakamura T‚ Yoshikawa T‚ Iida T‚ Miura Y‚ Kárpáti A‚ Matsuzawa T‚ Yanai A‚ Mogi A‚ Mochizuki T‚ Okamura N‚ Yanai K. Histamine N-methyltransferase regulates aggression and the sleep-wake cycle. Sci Rep. 2017 Nov 21;7(1):15899. |
| 38. | Lee H‚ Seo S‚ Lee SY‚ Jeong HJ‚ Woo SH‚ Lee KM‚ Lee YB‚ Park KH‚ Heo JH‚ Yoon CW‚ Kang JM‚ Cho J‚ Okamura N‚ Furumoto S‚ Yanai K‚ Na DL‚ Ido T‚ Villemagne VL‚ Noh Y. [18F]-THK5351 PET Imaging in patients with semantic variant primary progressive aphasia. Alzheimer Dis Assoc Disord. 2018 Jan-Mar;32(1):62-69. |
| 39. | Inoue S‚ Takahara S‚ Yoshikawa T‚ Niihori T‚ Yanai K‚ Matsubara Y‚ Aoki Y. Activated Braf induces esophageal dilation and gastric epithelial hyperplasia in mice. Hum Mol Genet. 2017 Dec 1;26(23):4715-4727. |
| 40. | Kang JM‚ Lee SY‚ Seo S‚ Jeong HJ‚ Woo SH‚ Lee H‚ Lee YB‚ Yeon BK‚ Shin DH‚ Park KH‚ Kang H‚ Okamura N‚ Furumoto S‚ Yanai K‚ Villemagne VL‚ Seong JK‚ Na DL‚ Ido T‚ Cho J‚ Lee KM‚ Noh Y. Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease. Neurobiol Aging. 2017 Nov;59:210-219. |
| 41. | Harada R‚ Ishiki A‚ Kai H‚ Sato N‚ Furukawa K‚ Furumoto S‚ Tago T‚ Tomita N‚ Watanuki S‚ Hiraoka K‚ Ishikawa Y‚ Funaki Y‚ Nakamura T‚ Yoshikawa T‚ Iwata R‚ Tashiro M‚ Sasano H‚ Kitamoto T‚ Yanai K‚ Arai H‚ Kudo Y‚ Okamura N. Correlations of 18F-THK5351 PET with post-mortem burden of tau and astrogliosis in Alzheimer's disease. J Nucl Med. 2017 in press. |
| 42. | Shidahara M‚ Thomas BA‚ Okamura N‚ Ibaraki M‚ Matsubara K‚ Oyama S‚ Ishikawa Y‚ Watanuki S‚ Iwata R‚ Furumoto S‚ Tashiro M‚ Yanai K‚ Gonda K‚ Watabe H. A comparison of five partial volume correction methods for Tau and Amyloid PET imaging with [18F]THK5351 and [11C]PIB. Ann Nucl Med. 2017 Aug;31(7):563-569. |
| 43. | Iida T‚ Yoshikawa T‚ Kárpáti A‚ Matsuzawa T‚ Kitano H‚ Mogi A‚ Harada R‚ Naganuma F‚ Nakamura T‚ Yanai K. JNJ10181457‚ a histamine H3 receptor inverse agonist‚ regulates in vivo microglial functions and improves depression-like behaviours in mice. Biochem Biophys Res Commun. 2017 Jul 1;488(3):534-540. |
| 44. | Iwata R‚ Pascali C‚ Terasaki K‚ Ishikawa Y‚ Furumoto S‚ Yanai K. Minimization of the amount of Kryptofix 222 - KHCO3 for applications to microscale 18F-radiolabeling. Appl Radiat Isot. 2017 Apr 13;125:113-118. |
| 45. | Kishimoto Y‚ Asakawa S‚ Sato T‚ Takano T‚ Nakajyo T‚ Mizuno N‚ Segawa R‚ Yoshikawa T‚ Hiratsuka M‚ Yanai K‚ Ohtsu H‚ Hirasawa N. Induced histamine regulates Ni elution from an implanted Ni wire in mice by downregulating neutrophil migration. Exp Dermatol. 2017 Oct;26(10):868-874. |
| 46. | Miura Y‚ Yoshikawa T‚ Naganuma F‚ Nakamura T‚ Iida T‚ Kárpáti A‚ Matsuzawa T‚ Mogi A‚ Harada R‚ Yanai K. Characterization of murine polyspecific monoamine transporters. FEBS Open Bio. 2017 Jan 9;7(2):237-248. |
| 47. | Inami A‚ Ogura T‚ Watanuki S‚ Masud MM‚ Shibuya K‚ Miyake M‚ Matsuda R‚ Hiraoka K‚ Itoh M‚ Fuhr AW‚ Yanai K‚ Tashiro M. Glucose Metabolic Changes in the Brain and Muscles of Patients with Nonspecific Neck Pain Treated by Spinal Manipulation Therapy: A [18F]FDG PET Study. Evid Based Complement Alternat Med. 2017;2017:4345703. |
| 48. | Shimozawa A‚ Ono M‚ Takahara D‚ Tarutani A‚ Imura S‚ Masuda-Suzukake M‚ Higuchi M‚ Yanai K‚ Hisanaga SI‚ Hasegawa M. Propagation of pathological α-synuclein in marmoset brain. Acta Neuropathol Commun. 2017 Feb 2;5(1):12. |
| 49. | Mizoguchi H‚ Watanabe C‚ Hayashi T‚ Iwata Y‚ Watanabe H‚ Katsuyama S‚ Hamamura K‚ Sakurada T‚ Ohtsu H‚ Yanai K‚ Sakurada S. The involvement of spinal release of histamine on nociceptive behaviors induced by intrathecally administered spermine. Eur J Pharmacol. 2017 Apr 5;800:9-15. |
| 50. | Arakawa Y‚ Nai Y‚ Shidahara M‚ Furumoto S‚ Seki C‚ Okamura N‚ Tashiro M‚ Kudo Y‚ Yanai K‚ Gonda K‚ Watabe H. Prediction of the clinical standardized uptake value ratio in amyloid PET imaging using a bio-mathematical modeling approach towards the efficient development of a radioligand. J Nucl Med. 2017 Jan 6. In press |
| 51. | Ishiki A‚ Harada R‚ Okamura N‚ Tomita N‚ Rowe CC‚ Villemagne VL‚ Yanai K‚ Kudo Y‚ Arai H‚ Furumoto S‚ Tashiro M‚ Furukawa K. Tau imaging with [18F]THK-5351 in progressive supranuclear palsy. Eur J Neurol. 2017 Jan;24(1):130-136. |
| 52. | Kikuchi A‚ Okamura N‚ Hasegawa T‚ Harada R‚ Watanuki S‚ Funaki Y‚ Hiraoka K‚ Baba T‚ Sugeno N‚ Oshima R‚ Yoshida S‚ Kobayashi J‚ Ezura M‚ Kobayashi M‚ Tano O‚ Mugikura S‚ Iwata R‚ Ishiki A‚ Furukawa K‚ Arai H‚ Furumoto S‚ Tashiro M‚ Yanai K‚ Kudo Y‚ Takeda A‚ Aoki M. In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology. 2016 Nov 29;87(22):2309-2316. |
| 53. | Tanaka Y‚ Kanazawa M‚ Kano M‚ Morishita J‚ Hamaguchi T‚ Van Oudenhove L‚ Ly HG‚ Dupont P‚ Tack J‚ Yamaguchi T‚ Yanai K‚ Tashiro M‚ Fukudo S. Differential Activation in Amygdala and Plasma Noradrenaline during Colorectal Distention by Administration of Corticotropin-Releasing Hormone between Healthy Individuals and Patients with Irritable Bowel Syndrome. PLoS One. 2016 Jul 22;11(7):e0157347 |
| 54. | Lockhart SN‚ Baker SL‚ Okamura N‚ Furukawa K‚ Ishiki A‚ Furumoto S‚ Tashiro M‚ Yanai K‚ Arai H‚ Kudo Y‚ Harada R‚ Tomita N‚ Hiraoka K‚ Watanuki S‚ Jagust WJ. Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351. PLoS One. 2016 Jun 29;11(6):e0158460. |
| 55. | Harada R‚ Furumoto S‚ Tago T‚ Katsutoshi F‚ Ishiki A‚ Tomita N‚ Iwata R‚ Tashiro M‚ Arai H‚ Yanai K‚ Kudo Y‚ Okamura N. Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351. Eur J Nucl Med Mol Imaging. 2016;43(12):2211-2218 |
| 56. | Inami A‚ Matsuda R‚ Grobosch T‚ Komamura H‚ Takeda K‚ Yamada Y‚ Miyake M‚ Hiraoka K‚ Maurer M‚ Yanai K‚ Tashiro M. A simulated car-driving study on the effects of acute administration of levocetirizine‚ fexofenadine‚ and diphenhydramine in healthy Japanese volunteers. Hum Psychopharmacol. 2016 May;31(3):167-77. |
| 57. | Sato K‚ Shidahara M‚ Watabe H‚ Watanuki S‚ Ishikawa Y‚ Arakawa Y‚ Nai YH‚ Furumoto S‚ Tashiro M‚ Shoji T‚ Yanai K‚ Gonda K. Performance evaluation of the small-animal PET scanner ClairvivoPET using NEMA NU 4-2008 Standards. Phys Med Biol. 2016 21;61(2):696-711. |
| 58. | Harada R‚ Furumoto S‚ Yoshikawa T‚ Ishikawa Y‚ Shibuya K‚ Okamura N‚ Ishiwata K‚ Iwata R‚ Yanai K. Synthesis and characterization of 18F-interleukin-8 using a cell-free translation system and 18F-fluoro-L-proline. J Nucl Med. 2016;57(4):634-9. |
| 59. | Harada R‚ Okamura N‚ Furumoto S‚ Furukawa K‚ Ishiki A‚ Tomita N‚ Tago T‚ Hiraoka K‚ Watanuki S‚ Shidahara M‚ Miyake M‚ Ishikawa Y‚ Matsuda R‚ Inami A‚ Yoshikawa T‚ Funaki Y‚ Iwata R‚ Tashiro M‚ Yanai K‚ Arai H‚ Kudo Y. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer's Disease. J Nucl Med. 2016;57(2):208-14. |
| 60. | Ishiki A‚ Okamura N‚ Furukawa K‚ Furumoto S‚ Harada R‚ Tomita N‚ Hiraoka K‚ Watanuki S‚ Ishikawa Y‚ Tago T‚ Funaki Y‚ Iwata R‚ Tashiro M‚ Yanai K‚ Kudo Y‚ Arai H. Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [18F]THK-5117 Positron Emission Tomography. PLoS One. 2015 13;10(10):e0140311. |
| 61. | Tago T‚ Furumoto S‚ Okamura N‚ Harada R‚ Adachi H‚ Ishikawa Y‚ Yanai K‚ Iwata R‚ Kudo Y. Preclinical Evaluation of [18F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer. Mol Imaging Biol. 2016;18(2):258-66. |
| 62. | Harada R‚ Okamura N‚ Furumoto S‚ Furukawa K‚ Ishiki A‚ Tomita N‚ Tago T‚ Hiraoka K‚ Watanuki S‚ Shidahara M‚ Miyake M‚ Ishikawa Y‚ Matsuda R‚ Inami A‚ Yoshikawa T‚ Funaki Y‚ Iwata R‚ Tashiro M‚ Yanai K‚ Arai H‚ Kudo Y. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer's Disease. J Nucl Med. 2015 Nov 5. pii: jnumed.115.164848. [Epub ahead of print] |
| 63. | Sato H‚ Ito C‚ Hiraoka K‚ Tashiro M‚ Shibuya K‚ Funaki Y‚ Yoshikawa T‚ Iwata R‚ Matsuoka H‚ Yanai K. Histamine H1 receptor occupancy by the new-generation antipsychotics olanzapine and quetiapine: a positron emission tomography study in healthy volunteers. Psychopharmacology (Berl). 2015 Oct;232(19):3497-505. |
| 64. | Hiraoka K‚ Narita W‚ Kikuchi H‚ Baba T‚ Kanno S‚ Iizuka O‚ Tashiro M‚ Furumoto S‚ Okamura N‚ Furukawa K‚ Arai H‚ Iwata R‚ Mori E‚ Yanai K. Amyloid deposits and response to shunt surgery in idiopathic normal-pressure hydrocephalus. J Neurol Sci. 2015 Sep 15;356(1-2):124-8. |
| 65. | Shidahara M‚ Watabe H‚ Tashiro M‚ Okamura N‚ Furumoto S‚ Watanuki S‚ Furukawa K‚ Arakawa Y‚ Funaki Y‚ Iwata R‚ Gonda K‚ Kudo Y‚ Arai H‚ Ishiwata K‚ Yanai K. Quantitative kinetic analysis of PET amyloid imaging agents [11C]BF227 and [18F]FACT in human brain. Nucl Med Biol. 2015 Sep;42(9):734-44. |
| 66. | Harada R‚ Okamura N‚ Furumoto S‚ Furukawa K‚ Ishiki A‚ Tomita N‚ Hiraoka K‚ Watanuki S‚ Shidahara M‚ Miyake M‚ Ishikawa Y‚ Matsuda R‚ Inami A‚ Yoshikawa T‚ Tago T‚ Funaki Y‚ Iwata R‚ Tashiro M‚ Yanai K‚ Arai H‚ Kudo Y. [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1052-61. |
| 67. | Iida T‚ Yoshikawa T‚ Matsuzawa T‚ Naganuma F‚ Nakamura T‚ Miura Y‚ Mohsen AS‚ Harada R‚ Iwata R‚ Yanai K. Histamine H3 receptor in primary mouse microglia inhibits chemotaxis‚ phagocytosis‚ and cytokine secretion. Glia. 2015 Jul;63(7):1213-25. |
| 68. | Nakamura T‚ Yoshikawa T‚ Naganuma F‚ Mohsen A‚ Iida T‚ Miura Y‚ Sugawara A‚ Yanai K. Role of histamine H3 receptor in glucagon-secreting αTC1.6 cells. FEBS Open Bio. 2014 Dec 13;5:36-41. |
| 69. | Murakami M‚ Yoshikawa T‚ Nakamura T‚ Ohba T‚ Matsuzaki Y‚ Sawamura D‚ Kuwasako K‚ Yanagisawa T‚ Ono K‚ Nakaji S‚ Yanai K. Involvement of the histamine H1 receptor in the regulation of sympathetic nerve activity. Biochem Biophys Res Commun. 2015 Mar 13;458(3):584-9. |
| 70. | Hiraoka K‚ Tashiro M‚ Grobosch T‚ Maurer M‚ Oda K‚ Toyohara J‚ Ishii K‚ Ishiwata K‚ Yanai K. Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine‚ a non-sedating antihistamine. Expert Opin Drug Saf. 2015 Feb;14(2):199-206. |
| 71. | Suzuki H‚ Sumiyoshi A‚ Matsumoto Y‚ Duffy BA‚ Yoshikawa T‚ Lythgoe MF‚ Yanai K‚ Taki Y‚ Kawashima R‚ Shimokawa H. Structural abnormality of the hippocampus associated with depressive symptoms in heart failure rats. Neuroimage. 2015 Jan 15;105:84-92. |
| 72. | Arai A‚ Kaneta T‚ Okamura N‚ Tashiro M‚ Iwata R‚ Takanami K‚ Fukuda H‚ Takahashi S‚ Yanai K‚ Kudo Y‚ Arai H. Pitfalls of voxel-based amyloid PET analyses for diagnosis of Alzheimer's disease: artifacts due to non-specific uptake in the white matter and the skull. Tohoku J Exp Med. 2014;234(3):175-81. |
| 73. | Yoshikawa T‚ Nakamura T‚ Shibakusa T‚ Sugita M‚ Naganuma F‚ Iida T‚ Miura Y‚ Mohsen A‚ Harada R‚ Yanai K. Insufficient intake of l-histidine reduces brain histamine and causes anxiety-like behaviors in male mice. J Nutr. 2014 Oct;144(10):1637-41 |
| 74. | Okamura N‚ Furumoto S‚ Fodero-Tavoletti MT‚ Mulligan RS‚ Harada R‚ Yates P‚ Pejoska S‚ Kudo Y‚ Masters CL‚ Yanai K‚ Rowe CC‚ Villemagne VL. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014 Jun;137(Pt 6):1762-71. |
| 75. | Fodero-Tavoletti MT‚ Furumoto S‚ Taylor L‚ McLean CA‚ Mulligan RS‚ Birchall I‚ Harada R‚ Masters CL‚ Yanai K‚ Kudo Y‚ Rowe CC‚ Okamura N‚ Villemagne VL. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non Alzheimer's disease tauopathies. Alzheimers Res Ther. 2014 Feb 26;6(1):11. |
| 76. | Mohsen A‚ Yoshikawa T‚ Miura Y‚ Nakamura T‚ Naganuma F‚ Shibuya K‚ Iida T‚ Harada R‚ Okamura N‚ Watanabe T‚ Yanai K. Mechanism of the histamine H3 receptor-mediated increase in exploratory locomotor activity and anxiety-like behaviours in mice. Neuropharmacology. 2014 Jun;81:188-94. |
| 77. | Villemagne VL‚ Furumoto S‚ Fodero-Tavoletti MT‚ Mulligan RS‚ Hodges J‚ Harada R‚ Yates P‚ Piguet O‚ Pejoska S‚ Doré V‚ Yanai K‚ Masters CL‚ Kudo Y‚ Rowe CC‚ Okamura N. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2014 May;41(5):816-26. |
| 78. | Naganuma F‚ Yoshikawa T‚ Nakamura T‚ Iida T‚ Harada R‚ Mohsen AS‚ Miura Y‚ Yanai K. Predominant role of plasma membrane monoamine transporters in monoamine transport in 1321N1‚ a human astrocytoma-derived cell line. J Neurochem. 2014 May;129(4):591-601. |
| 79. | Kaneta T‚ Okamura N‚ Arai A‚ Takanami K‚ Furukawa K‚ Tashiro M‚ Furumoto S‚ Iwata R‚ Takahashi S‚ Arai H‚ Yanai K‚ Kudo Y. Analysis of early phase [11C]BF-227 PET‚ and its application for anatomical standardization of late-phase images for 3D-SSP analysis. Jpn J Radiol. 2014 Mar;32(3):138-44. |
| 80. | Guo Y‚ Niu K‚ Okazaki T‚ Wu H‚ Yoshikawa T‚ Ohrui T‚ Furukawa K‚ Ichinose M‚ Yanai K‚ Arai H‚ Huang G‚ Nagatomi R. Coffee treatment prevents the progression of sarcopenia in aged mice in vivo and in vitro. Exp Gerontol. 2014 Feb;50:1-8. |
| 81. | Ito H‚ Shinotoh H‚ Shimada H‚ Miyoshi M‚ Yanai K‚ Okamura N‚ Takano H‚ Takahashi H‚ Arakawa R‚ Kodaka F‚ Ono M‚ Eguchi Y‚ Higuchi M‚ Fukumura T‚ Suhara T. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB. Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):745-54 |
| 82. | Yoneda H‚ Niijima-Yaoita F‚ Tsuchiya M‚ Kumamoto H‚ Watanbe M‚ Ohtsu H‚ Yanai K‚ Tadano T‚ Sasaki K‚ Sugawara S‚ Endo Y. Roles played by histamine in strenuous or prolonged masseter muscle activity in mice. Clin Exp Pharmacol Physiol. 2013 Dec;40(12):848-55. |
| 83. | Nakamura T‚ Yoshikawa T‚ Noguchi N‚ Sugawara A‚ Kasajima A‚ Sasano H‚ Yanai K. The expression and function of histamine H₃ receptors in pancreatic beta cells. Br J Pharmacol. 2014 Jan;171(1):171-85 |
| 84. | Harada R‚ Okamura N‚ Furumoto S‚ Yoshikawa T‚ Arai H‚ Yanai K‚ Kudo Y. Use of a benzimidazole derivative BF-188 in fluorescence multispectral imaging for selective visualization of tau protein fibrils in the Alzheimer's disease brain. Mol Imaging Biol. 2014 Feb;16(1):19-27. |
| 85. | Tago T‚ Furumoto S‚ Okamura N‚ Harada R‚ Ishikawa Y‚ Arai H‚ Yanai K‚ Iwata R‚ Kudo Y. Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging. J Label Compd Radiopharm. 2014 Jan;57(1):18-24. |
| 86. | Okamura N‚ Furumoto S‚ Harada R‚ Tago T‚ Yoshikawa T‚ Fodero-Tavoletti M‚ Mulligan RS‚ Villemagne VL‚ Akatsu H‚ Yamamoto T‚ Arai H‚ Iwata R‚ Yanai K‚ Kudo Y. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013; 54(8):1420-7. |
| 87. | Furumoto S‚ Shinbo R‚ Iwata R‚ Ishikawa Y‚ Yanai K‚ Yoshioka T‚ Fukuda H. In vitro and in vivo characterization of 2-deoxy-2-18F-fluoro-D-mannose as a tumor-imaging agent for PET. J Nucl Med. 2013; 54(8):1354-61. |
| 88. | Sato H‚ Ito C‚ Tashiro M‚ Hiraoka K‚ Shibuya K‚ Funaki Y‚ Iwata R‚ Matsuoka H‚ Yanai K. Histamine H1 receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers.Psychopharmacology (Berl). 2013 Nov;230(2):227-34. |
| 89. | Hamaguchi T‚ Kano M‚ Kanazawa M‚ Itoh M‚ Yanai K‚ Fukudo S. Effects of Preceding Stimulation on Brain Activation in Response to Colonic Distention in Humans.Psychosom Med. 2013 Jun;75(5):453-62. |
| 90. | Niu K‚ Guo H‚ Guo Y‚ Ebihara S‚ Asada M‚ Ohrui T‚ Furukawa K‚ Ichinose M‚ Yanai K‚ Kudo Y‚ Arai H‚ Okazaki T‚ Nagatomi R. Royal Jelly Prevents the Progression of Sarcopenia in Aged Mice In Vivo and In Vitro. J Gerontol A Biol Sci Med Sci. 2013 Dec;68(12):1482-92. |
| 91. | Shidahara M‚ Tashiro M‚ Okamura N‚ Furumoto S‚ Furukawa K‚ Watanuki S‚ Hiraoka K‚ Miyake M‚ Iwata R‚ Tamura H‚ Arai H‚ Kudo Y‚ Yanai K. Evaluation of the biodistribution and radiation dosimetry of the 18F-labelled amyloid imaging probe [18F]FACT in humans. EJNMMI Res. 2013 Apr 24;3(1):32. doi: 10.1186/2191-219X-3-32. |
| 92. | Yoshikawa T‚ Naganuma F‚ Iida T‚ Nakamura T‚ Harada R‚ Mohsen AS‚ Kasajima A‚ Sasano H‚ Yanai K. Molecular mechanism of histamine clearance by primary human astrocytes. Glia. 2013 Jun;61(6):905-16. |
| 93. | Furumoto S‚ Okamura N‚ Furukawa K‚ Tashiro M‚ Ishikawa Y‚ Sugi K‚ Tomita N‚ Waragai M‚ Harada R‚ Tago T‚ Iwata R‚ Yanai K‚ Arai H‚ Kudo Y. A 18F-Labeled BF-227 Derivative as a Potential Radioligand for Imaging Dense Amyloid Plaques by Positron Emission Tomography. Mol Imaging Biol. 2013 in press |
| 94. | Harada R‚ Okamura N‚ Furumoto S‚ Tago T‚ Maruyama M‚ Higuchi M‚ Yoshikawa T‚ Arai H‚ Iwata R‚ Kudo Y‚ Yanai K. Comparison of the binding characteristics of [(18)F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):125-32. doi: 10.1007/s00259-012-2261-2. Epub 2012 Oct 26. |
| 95. | Matsuda T‚ Furumoto S‚ Higuchi K‚ Yokoyama J‚ Zhang MR‚ Yanai K‚ Iwata R‚ Kigawa T. Rapid biochemical synthesis of (11)C-labeled single chain variable fragment antibody for immuno-PET by cell-free protein synthesis. Bioorg Med Chem. 2012 Nov 15;20(22):6579-82. doi: 10.1016/j.bmc.2012.09.038. Epub 2012 Sep 25. |
| 96. | Hiraoka K‚ Okamura N‚ Funaki Y‚ Hayashi A‚ Tashiro M‚ Hisanaga K‚ Fujii T‚ Takeda A‚ Yanai K‚ Iwata R‚ Mori E. Cholinergic Deficit and Response to Donepezil Therapy in Parkinson's Disease with Dementia. Eur Neurol. 2012 ;68(3):137-143 |
| 97. | Shibuya K‚ Funaki Y‚ Hiraoka K‚ Yoshikawa T‚ Naganuma F‚ Miyake M‚ Watanuki S‚ Sato H‚ Tashiro M‚ Yanai K. [11C]Doxepin binding to histamine H1 receptors in living human brain: reproducibility during attentive waking and circadian rhythm. Front Syst Neurosci. 2012;6:45. |
| 98. | Tomita N‚ Furukawa K‚ Okamura N‚ Tashiro M‚ Une K‚ Furumoto S‚ Iwata R‚ Yanai K‚ Kudo Y‚ Arai H. Brain accumulation of amyloid β protein visualized by positron emission tomography and BF-227 in Alzheimer's disease patients with or without diabetes mellitus. Geriatr Gerontol Int. 2012 Jun 10. |
| 99. | Ogura T‚ Tashiro M‚ Masud M‚ Watanuki S‚ Shibuya K‚ Yamaguchi K‚ Itoh M‚ Fukuda H‚ Yanai K. Cerebral metabolic changes in men after chiropractic spinal manipulation for neck pain. Altern Ther Health Med. 2011;17(6):12-7 |
| 100. | Furukawa K‚ Ikeda S‚ Okamura N‚ Tashiro M‚ Tomita N‚ Furumoto S‚ Iwata R‚ Yanai K‚ Kudo Y‚ Arai H. Cardiac positron-emission tomography images with an amyloid-specific tracer in familial transthyretin-related systemic amyloidosis. Circulation. 2012;125(3):556-7. |
| 101. | Niijima-Yaoita F‚ Tsuchiya M‚ Ohtsu H‚ Yanai K‚ Sugawara S‚ Endo Y‚ Tadano T. Roles of histamine in exercise-induced fatigue: favouring endurance and protecting against exhaustion. Biol Pharm Bull. 2012;35(1):91-7. |
| 102. | Harada R‚ Furumoto S‚ Yoshikawa T‚ Ishikawa Y‚ Shibuya K‚ Okamura N‚ Iwata R‚ Yanai K. Synthesis of [11C]interleukin 8 using a cell-free translation system and l-[11C]methionine. Nucl Med Biol. 2012 ;39(1):155-60. |
| 103. | Kaneta T‚ Okamura N‚ Minoshima S‚ Furukawa K‚ Tashiro M‚ Furumoto S‚ Iwata R‚ Fukuda H‚ Takahashi S‚ Yanai K‚ Kudo Y‚ Arai H. A modified method of 3D-SSP analysis for amyloid PET imaging using [11C]BF-227. Ann Nucl Med. 2011;25(10):732-9. |
| 104. | Kuramasu A‚ Sukegawa J‚ Sato T‚ Sakurai E‚ Watanabe T‚ Yanagisawa T‚ Yanai K. The hydrophobic amino acids in putative helix 8 in carboxy-terminus of histamine H3 receptor are involved in receptor-G-protein coupling. Cell Signal. 2011; 23(11): 1843-9. |
| 105. | Kasuya M‚ Meguro K‚ Okamura N‚ Funaki Y‚ Ishikawa H‚ Tanaka N‚ Iwata R‚ Yanai K. Greater Responsiveness to Donepezil in Alzheimer Patients With Higher Levels of Acetylcholinesterase Based on Attention Task Scores and a Donepezil PET Study. Alzheimer Dis Assoc Disord. 2011 Jun 9. |
| 106. | Mobarakeh JI‚ Torkaman-Boutorabi A‚ Rahimi AA‚ Ghasri S‚ Nezhad RM‚ Hamzely A‚ Khoshkholgh Sima B‚ Takahashi K‚ Nunoki K‚ Yanai K. Interaction of histamine and calcitonin gene-related peptide in the formalininduced pain perception in rats. Biomed Res. 2011;32(3):195-201. |
| 107. | Fodero-Tavoletti MT‚ Okamura N‚ Furumoto S‚ Mulligan RS‚ Connor AR‚ McLean CA‚ Cao D‚ Rigopoulos A‚ Cartwright GA‚ O'Keefe G‚ Gong S‚ Adlard PA‚ Barnham KJ‚ Rowe CC‚ Masters CL‚ Kudo Y‚ Cappai R‚ Yanai K‚ Villemagne VL. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain. 2011;134 :1089-100. |
| 108. | Kubo N‚ Senda M‚ Ohsumi Y‚ Sakamoto S‚ Matsumoto K‚ Tashiro M‚ Okamura N‚ Yanai K. Brain histamine H1 receptor occupancy of loratadine measured by PET: Comparison of H1 receptor occupancy and proportional impairment ratio. Hum Psychopharmacol. 2011; 26(2):133-139 |
| 109. | Xu A‚ Sakurai E‚ Kuramasu A‚ Zhang J‚ Li J‚ Okamura N‚ Zhang D‚ Yoshikawa T‚ Watanabe T‚ Yanai K. Roles of hypothalamic subgroup histamine and orexin neurons on behavioral responses to sleep deprivation induced by the treadmill method in adolescent rats. J. Pharmacol. Sci. 2010;114(4): 444-53. |
| 110. | Okamura N‚ Mori M‚ Furumoto S‚ Yoshikawa T‚ Harada R‚ Ito S‚ Fujikawa Y‚ Arai H‚ Yanai K‚ Kudo Y. In vivo Detection of Amyloid Plaques in the Mouse Brain using the Near-Infrared Fluorescence Probe THK-265. J Alzheimers Dis. 2011; 23: 37-48 |
| 111. | Zhang D‚ Tashiro M‚ Shibuya K‚ Okamura N‚ Funaki Y‚Yoshikawa T‚ Kato M‚ Yanai K. Next-day Residual Sedative Effect after Nighttime Administration of an OTC Antihistamine Sleepaid‚ Diphenhydramine‚ Measured by Positron Emission Tomography. J. Clin. Psychopharmacol. 2010; 30(6): 694-701. |
| 112. | Shao H‚ Okamura N‚ Sugi K‚ Furumoto S‚ Furukawa K‚ Tashiro M‚ Iwata R‚ Matsuda H‚ Kudo Y‚ Arai H‚ Fukuda H‚ Yanai K.Voxel-Based Analysis of Amyloid Positron Emission Tomography Probe [11C]BF-227 Uptake in Mild Cognitive Impairment and Alzheimer's Disease. Dement Geriatr Cogn Disord. 30(2):101-111 (2010) |
| 113. | Lü YQ‚ He RR‚ Watanabe H‚ Abe K‚ Sakurai E‚ Yanai K‚ Kurihara H. Effects of a chicken extract on food-deprived activity stress in rats. Biosci Biotechnol Biochem. 74(6):1276-1278 (2010) |
| 114. | Seki Y‚ Akanmu MA‚ Matsuura M‚ Yanai K‚ Honda K. Alpha-fluoromethylhistidine‚ a histamine synthesis inhibitor‚ inhibits orexin-induced wakefulness in rats. Behav. Brain Res. 207: 151-154 (2010) |
| 115. | Kikuchi A‚ Takeda A‚ Okamura N‚ Tashiro M‚ Hasegawa T‚ Furumoto S‚ Kobayashi M‚ Sugeno N‚ Baba T‚ Miki Y‚ Mori F‚ Wakabayashi K‚ Funaki Y‚ Iwata R‚ Takahashi S‚ Fukuda H‚ Arai H‚ Kudo Y‚ Yanai K‚ Itoyama Y. In vivo visualization of {alpha}-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl) ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain. 133(Pt 6):1772-1778 (2010) |
| 116. | Watanuki S‚ Tashiro M‚ Miyake M‚ Ishikawa Y‚ Itoh M‚ Yanai K‚ Sakemi Y‚ Fukuda H‚ Ishii K. Long-term performance evaluation of positron emission tomography: analysis and proposal of a maintenance protocol for long-term utilization. Ann Nucl Med. 24(6):461-468 (2010) |
| 117. | Okamura N‚ Shiga Y‚ Furumoto S‚ Tashiro M‚ Tsuboi Y‚ Furukawa K‚ Yanai K‚ Iwata R‚ Arai H‚ Kudo Y‚ Itoyama Y‚ Doh-ura K. In vivo detection of prion amyloid plaques using [11C]BF-227 PET. Eur J Nucl Med Mol Imaging. 37(5):934-941 (2010) |
| 118. | Furukawa K‚ Okamura N‚ Tashiro M‚ Waragai M‚ Furumoto S‚ Iwata R‚ Yanai K‚ Kudo Y‚ Arai H. Amyloid PET in mild cognitive impairment and Alzheimer’s disease with BF-227: Comparison to FDG-PET. J Neurol. 257(5):721-727 (2010) |
| 119. | Okuda T‚ Zhang D‚ Shao H‚ Okamura N‚ Takino N‚ Iwamura T‚ Sakurai E‚ Yoshikawa T‚ Yanai K. Methamphetamine- and 3‚4-Methylenedioxymethamphetamine-Induced Behavioral Changes in Histamine H(3)-Receptor Knockout Mice. J Pharmacol Sci. 2009 Oct;111(2):167-74. |
| 120. | Tashiro M‚ Kato M‚ Miyake M‚ Watanuki S‚ Funaki Y‚ Ishikawa Y‚ Iwata R‚ Yanai K. Dose dependency of brain histamine H(1) receptor occupancy following oral administration of cetirizine hydrochloride measured using PET with [11C]doxepin. Hum Psychopharmacol. 2009 Oct;24(7):540-8. |
| 121. | Takino N‚ Sakurai E‚ Kuramasu A‚ Okamura N‚ Yanai K. Roles of the histaminergic neurotransmission on methamphetamine-induced locomotor sensitization and reward: a study of receptors gene knockout mice. Int Rev Neurobiol. 2009;85:109-16. |
| 122. | Mobarakeh JI‚ Takahashi K‚ Yanai K. Enhanced morphine-induced antinociception in histamine H3 receptor gene knockout mice. Neuropharmacology. 2009 Sep;57(4):409-14. |
| 123. | Fodero-Tavoletti MT‚ Mulligan RS‚ Okamura N‚ Furumoto S‚ Rowe CC‚ Kudo Y‚ Masters CL‚ Cappai R‚ Yanai K‚ Villemagne VL. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy Bodies. Eur J Pharmacol. 2009 Sep 1;617(1-3):54-8. |
| 124. | Waragai M‚ Okamura N‚ Furukawa K‚ Tashiro M‚ Furumoto S‚ Funaki Y‚ Kato M‚ Iwata R‚ Yanai K‚ Kudo Y‚ Arai H. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease. J Neurol Sci. 2009 Oct 15;285(1-2):100-8. |
| 125. | Fukudo S‚ Kanazawa M‚ Mizuno T‚ Hamaguchi T‚ Kano M‚ Watanabe S‚ Sagami Y‚ Shoji T‚ Endo Y‚ Hongo M‚ Itoyama Y‚ Yanai K‚ Tashiro M‚ Aoki M. Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention. Neuroimage. 2009 Sep;47(3):946-51. |
| 126. | Hiraoka K‚ Okamura N‚ Funaki Y‚ Watanuki S‚ Tashiro M‚ Kato M‚ Hayashi A‚ Hosokai Y‚ Yamasaki H‚ Fujii T‚ Mori E‚ Yanai K‚ Watabe H. Quantitative analysis of donepezil binding to acetylcholinesterase using positron emission tomography and [5-(11)C-methoxy]donepezil. Neuroimage. 2009 Jul 1;46(3):616-23. |
| 127. | Ogawa S‚ Yanai K‚ Watanabe T‚ Wang ZM‚ Akaike H‚ Ito Y‚ Akaike N. Histamine responses of large neostriatal interneurons in histamine H1 and H2 receptor knock-out mice. Brain Res Bull. 78(4-5):189-94 (2009) |
| 128. | Nishino S‚ Sakurai E‚ Nevsimalova S‚ Yoshida Y‚ Watanabe T‚ Yanai K‚ Mignot E. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep 32(2):175-80 (2009) |
| 129. | Yoshizawa M‚ Tashiro M‚ Fukudo S‚ Yanai K‚ Utsumi A‚ Kano M‚ Karahasi M‚ Endo Y‚ Morisita J‚ Sato Y‚ Adachi M‚ Itoh M‚ Hongo M. Increased Brain Histamine H1 Receptor Binding in Patients with Anorexia Nervosa. Biol Psychiatry 65(4):329-35 (2009) |
| 130. | Xu AJ‚ Kuramasu A‚ Maeda K‚ Kinoshita K‚ Takayanagi S‚ Fukushima Y‚ Watanabe T‚ Yanagisawa T‚ Sukegawa J‚ Yanai K. Agonist-induced internalization of histamine H2 receptor and activation of extracellular signal-regulated kinases are dynamin-dependent. J Neurochem 107: 208-217 (2008) |
| 131. | Suzuki M‚ Okamura N‚ Kawachi Y‚ Tashiro M‚ Arao H‚ Hoshishiba T‚ Gyoba J‚ Yanai K. Discrete cortical regions associated with the musical beauty of major and minor chords. Cogn Affect Behav Neurosci. 2008; 8(2):126-31. |
| 132. | Jia F‚ Mobarakeh JI‚ Dai H‚ Kato M‚ Xu A‚ Okuda T‚ Sakurai E‚ Okamura N‚ Takahashi K‚ Yanai K. Blocking histamine H1 improves learning and mnemonic dysfunction in mice with social isolation plus repeated methamphetamine injection. J Pharmacol Sci. 2008;107(2):167-74. |
| 133. | Tashiro M‚ Itoh M‚ Fujimoto T‚ Masud MM‚ Watanuki S‚ Yanai K. Application of positron emission tomography to neuroimaging in sports sciences. Methods. 45(4):300-6. 2008 |
| 134. | Tashiro M‚ Duan X‚ Kato M‚ Miyake M‚ Watanuki S‚ Ishikawa Y‚ Funaki Y‚ Iwata R‚ Itoh M‚ Yanai K. Brain histamine H1 receptor occupancy of orally administered antihistamines‚ bepotastine and diphenhydramine‚ measured by PET with 11C-doxepin. Br J Clin Pharmacol. 2008 Jun;65(6):811-21. |
| 135. | Maeda K‚ Haraguchi M‚ Kuramasu A‚ Sato T‚ Ariake K‚ Sakagami H‚ Kondo H‚ Yanai K‚ Fukunaga K‚ Yanagisawa T‚ Sukegawa J. CLIC4 interacts with histamine H3 receptor and enhances the receptor cell surface expression. Biochem Biophys Res Commun. 2008 May 2;369(2):603-8. |
| 136. | Tashiro M‚ Sakurada Y‚ Mochizuki H‚ Horikawa E‚ Maruyama M‚ Okamura N‚ Watanuki S‚ Arai H‚ Itoh M‚ Yanai K. Effects of a sedative antihistamine‚ D-chlorpheniramine‚ on regional cerebral perfusion and performance during simulated car driving. Hum Psychopharmacol. 2008 Mar;23(2):139-50. |
| 137. | Okamura N‚ Furumoto S‚ Funaki Y‚ Suemoto T‚ Kato M‚ Ishikawa Y‚ Ito S‚ Akatsu H‚ Yamamoto T‚ Sawada T‚ Arai H‚ Kudo Y‚ Yanai K. Binding and safety profile of novel benzoxazole derivative for in vivo imaging of amyloid deposits in Alzheimer’s disease. Geriatr Gerontol Int. 2007; 7: 393-400. |
| 138. | Watanabe C‚ Orito T‚ Watanabe H‚ Mizoguchi H‚ Yonezawa A‚ Yanai K‚ Mobarakeh JI‚ Onodera K‚ Sakurada T‚ Sakurada S. Intrathecal high-dose histamine induces spinally-mediated nociceptive behavioral responses through a polyamine site of NMDA receptors. Eur J Pharmacol. 2008 Feb 26;581(1-2):54-63. |
| 139. | Okamura N‚ Funaki Y‚ Tashiro M‚ Kato M‚ Ishikawa Y‚ Maruyama M‚ Ishikawa H‚ Meguro K‚ Iwata R‚ Yanai K. In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease.Br J Clin Pharmacol. 2008 Apr;65(4):472-9. |
| 140. | Funaki Y‚ Sato K‚ Kato M‚ Ishikawa Y‚ Iwata R‚ Yanai K. Evaluation of the binding characteristics of [(18)F]fluoroproxyfan in the rat brain for in vivo visualization of histamine H(3) receptor. Nucl Med Biol. 2007 Nov; 34(8):981-7. |
| 141. | Mochizuki H‚ Tashiro M‚ Gyoba J‚ Suzuki M‚ Okamura N‚ Itoh M‚ Yanai K. Brain activity associated with dual-task management differs depending on the combinations of response modalities. Brain Res. 1172C:82-92 (2007) |
| 142. | Murakami M‚ Nakagawasai O‚ Yanai K‚ Nunoki K‚ Tan-No K‚ Tadano T‚ Iijima T. Modified behavioral characteristics following ablation of the voltage-dependent calcium channel beta3 subunit. Brain Res. 1160: 102-112 (2007) |
| 143. | Kudo Y‚ Okamura N‚ Furumoto S‚ Tashiro M‚ Furukawa K‚ Maruyama M‚ Itoh M‚ Iwata R‚ Yanai K‚ Arai H. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy) benzoxazole: A novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J. Nucl. Med. 48(4):553-561 (2007) |
| 144. | Kano M‚ Hamaguchi T‚ Itoh M‚ Yanai K‚ Fukudo S. Correlation between alexithymia and hypersensitivity to visceral stimulation in human. Pain 132(3):252-63 (2007) |
| 145. | Mochizuki H‚ Sadato H‚ Saito D. N.‚ Toyoda H‚ Tashiro M‚ Okamura N‚ Yanai K. Neural correlates of perceptual difference between itching and pain: A human fMRI study. Neuroimage 36: 706-717 (2007) |
| 146. | Dai H‚ Kaneko K‚ Kato H‚ Fujii S‚ Jing Y‚ Sakurai E‚ Kato M‚ Okamura N‚ Kuramasu A‚ Yanai K. Selective cognitive dysfunction in mice lacking histamine H1 and H2 receptors. Neuroscience Research 57(2):306-13 (2007) |
| 147. | Ishiwata K‚ Kawamura K‚ Yanai K‚ Hendrikse H.N. In Vivo Evaluation of P-Glycoprotein Modulation of 8 PET Radioligands Used Clinically. J Nucl Med 48:81–87 (2007) |
| 148. | Sakurai E‚ Sakurai E‚ Oreland L‚ Nishiyama S‚ Kato M‚ Watanabe T‚ and K. Yanai. Evidence for the presence of histamine uptake into the synaptosomes of rat brain. Pharmacology 78(2):72-80 (2006) |
| 149. | Mobarakeh J I‚ Takahashi K‚ Sakurada S‚ Kuramasu A‚ Yanai K. Enhanced antinociceptive effects of morphine in histamine H2 receptor gene knockout mice. Neuropharmacology 51(3): 612-22 (2006). |
| 150. | Owada Y‚ Abdelwahab S A‚ Kitanaka N‚ Sakagami H‚ Takano H‚ Sugitani Y‚ Sugawara M‚ Kawashima H‚ Kiso Y‚ Mobarakeh J I‚ Yanai K‚ Kaneko K‚ Sasaki H‚ Kato H‚ Saino-Saito S‚ Matsumoto N‚ Akaike N‚ Noda T‚ and Kondo H. Altered emotional behavioral responses in mice lacking brain-type fatty acid-binding protein gene. Eur. J. Neurosci. 24(1):175-87 (2006). |
| 151. | FY Jia‚ M. Kato‚ H. Dai‚ AJ Xu‚ T. Okuda‚ E. Sakurai‚ N. Okamura‚ T. W. Lovenberg‚ A. Barbier‚ N. I. Carruthers‚ K. Iinuma‚ K. Yanai. Effects of histamine H3 antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice. Neuropharmacology 50(4):404-411 (2006) |
| 152. | Tashiro M‚ Mochizuki H‚ Sakurada Y‚ Ishii K‚ Oda K‚ Kimura Y‚ Sasaki T‚ Ishiwata K‚ Yanai K. Brain histamine H1 receptor occupancy of orally-administered antihistamines measured by positron emission tomography with 11C-doxepin in a placebo-controlled crossover study-design in healthy volunteers: a comparison of olopatadine and ketotifen. Br. J. Clin. Pharmacol. 61(1): 16-26 (2006) |
| 153. | Okamura N‚ Suemoto T‚ Furumoto S‚ Suzuki M‚ Shimadzu H‚ Akatsu H‚ Yamamoto T‚ Fujiwara H‚ Nemoto M‚ Maruyama M‚ Arai H‚ Yanai K‚ Sawada T‚ Kudo Y.Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci. 25(47):10857-10862 (2005) |
| 154. | Dai H‚ Okuda T‚ Sakurai E‚ Kuramasu A‚ Kato M‚ Jia FY‚ Xu AJ‚ Iinuma K‚ Sato I‚ Yanai K. Blockage of histamine H1 receptor attenuates social isolation-induced disruption of pre-pulse inhibition: A study in H1 receptor gene knockout mice. Psychopharmacology 183(3):285-293 (2005) |
| 155. | Mobarakeh J I‚ Takahashi K‚ Sakurada S‚ Nishino S‚ Watanabe H‚ Kato M‚ Naghdi N‚ Yanai K. Enhanced antinociception by intracerebroventricularly administered orexin A in histamine H1 or H2 receptor gene knockout mice. Pain 118(1-2):254-262 (2005) |
| 156. | Yoshida A‚ Mobarakeh J. I.‚ Sakurai E‚ Sakurada S‚ Hayashi T‚ Orito T‚ Watanabe H‚ Kuramasu A‚ Kato M‚ Yanai K. Intrathecally-administered histamine facilitates nociception through tachykinin NK1 and histamine H1 receptors: A study in histidine decarboxylase gene knockout mice. Eur. J. Pharmacol. 522(1-3):55-62 (2005). |
| 157. | Suzuki A‚ Tashiro M‚ Kimura Y‚ Mochizuki H‚ Ishii K‚ Watabe H‚ Yanai K‚ Ishiwata K‚ Ishii K. Use of reference tissue models for quantification of histamine H1 receptors in human brain by using positron emission tomography and [11C]doxepin. Ann Nucl. Med. 19 (6): 425-433 (2005) |
| 158. | Tashiro M‚ Horikawa E‚ Mochizuki H‚ Sakurada Y‚ Kato M‚ Inokuchi T‚ Ridout F‚ Hindmarch I‚ Yanai K. Effects of fexofenadine and hydroxyzine on brake reaction time Hum. Psychopharmacol. 20: 501–509 (2005). |
| 159. | Suzuki H‚ J. I. Mobarakeh‚ Nunoki K‚ Sukegawa J‚ Watanabe H‚ Kuramasu A‚ Watanabe T‚ Yanai K‚ Yanagisawa T. Effects of activation of central nervous histamine receptors in cardiovascular regulation; studies in H1 and H2 receptor gene knockout mice. Naunyn Schmiedebergs Arch Pharmacol. 371(2):99-106 (2005) |
| 160. | Horikawa E‚ Okamura N‚ Tashiro M‚ Sakurada Y‚ Maruyama M‚ Arai H‚ Yamaguchi K‚ Sasaki H‚ Yanai K‚ Itoh M. The neural correlates of driving performance identified using positron emission tomography. Brain Cogn. 58(2):166-171(2005) |
| 161. | Iwabuchi K‚ Ito C‚ Tashiro M‚ Mochizuki H‚ Kato M‚ Kano M‚ Ishii K‚ Ishiwata K‚ Itoh M‚ Iwata R‚ Matsuoka H‚ Sato M‚ and Yanai K. A PET study of histamine H1 receptors in the schizophrenic patients assessed by [11C]doxepin. Eur Neuropsychopharmacol. 15(2):185-191 (2005). |
| 162. | J. I. Mobarakeh‚ K. Takahashi‚ S. Sakurada‚ S. Nishino‚ H. Watanabe‚ M. Kato‚ K. Yanai. Enhanced antinociception by intracerebroventricularly and intrathecally- administered orexin A and B in mice. Peptides 26(5): 767-777 (2005) |
| 163. | Okuda T‚ Ito Y‚ Nakagawa N‚ Hishinuma T‚ Tsukamoto H‚ Iwabuchi K‚ Watanabe T‚ Kitaichi K‚ Goto J‚ Yanai K. Drug interaction between methamphetamine and antihistamines : behavioral changes and tissue concentration of methamphetamine in rats. Eur. J. Pharmacol. 505: 135-144 (2004) |
| 164. | Mochizuki H‚ Kimura Y‚ Ishii K‚ Oda K‚ Sasaki T‚ Tashiro M‚ Yanai K‚ Ishiwata K. Simplified PET measurement for evaluating histamine H1 receptors in human brains using [11C]doxepin. Nucl. Med. Biol. 31(8):1005-1011 (2004) |
| 165. | Ohinata K‚ Shimano T‚ Yamauchi R‚ Sakurada S‚ Yanai K‚ Yoshikawa M. The anorectic effect of neurotensin is mediated via a histamine H1 receptor in mice. Peptides 12:2135-2138 (2004). |
| 166. | Chen Z‚ Sakurai E‚ Hu W‚ Jin C‚ Kiso Y‚ Kato M‚ Watanabe T‚ Wei E‚ Yanai K. Pharmacological function of carcinine on histaminergic neurons in the brain. Br. J. Pharmacol. 143(5):573-580 (2004) |
| 167. | S. Sakurada‚ H. Watanabe‚ H. Mizoguchi‚ A. Yonezawa‚ T. Orito‚ S. Katsuyama‚ A. Kuramasu‚ C. Sakurada‚ K. Yanai‚ T. Sakurada. Involvement of the histaminergic system in the nociceptin-induced pain-related behaviors in the mouse spinal cord. Pain 112(1-2): 171-182 (2004) |
| 168. | Murakami‚ M.‚ Nakagawasai‚ O.‚ Suzuki‚ T.‚ Mobarakeh‚ I.I.‚ Sakurada‚ Y.‚ Murata‚ A.‚ Yamadera‚ F.‚ Miyoshi‚ I.‚ Yanai‚ K.‚ Tan-No‚ K.‚ Sasano‚ H.‚ Tadano‚ T.‚ and Iijima T. Antinociceptive effect of different types of calcium channel inhibitors and the distribution of various calcium channel α1 subunits in the dorsal horn of spinal cord in mice. Brain Res. 1024(1-2):122-129 (2004). |
| 169. | Ojima T‚ Ito C‚ Sakurai E‚ Sakurai E‚ Watanabe T‚ Yanai K. Effects of serotonin-dopamine antagonist on prepulse inhibition and neurotransmitter contents in the rat brain. Neurosci. Lett. 366: 130-134 (2004) |
| 170. | Murakami M‚ Mori T‚ Nakagawasai O‚ Hagiwara K‚ Sakurada Y‚ Mobarakeh I. J.‚ Murata A‚ Yamadera F‚ Miyoshi I‚ Tan-No K‚ Yanai K‚ Tadano T‚ Iijima T. Inhibitory effect of pranidipine on N-type voltage-dependent Ca2+ channels in mice. Neurosci Lett. 367: 118-122 (2004) |
| 171. | Kano M‚ Fukudo S‚ Tashiro A‚ Utsumi A‚ Tamaru D‚ Itoh M‚ Iwata R‚ Tashiro M‚ Mochizuki H‚ Funaki Y‚ Kato M‚ Hongo M‚ Yanai K. Decreased histamine H1 receptor binding in the brain of depressed patients. Eur. J. Neurosci. 20(3):803-10 (2004). |
| 172. | M. Tashiro‚ Sakurada Y‚ Iwabuchi K‚ Mochizuki H‚ Kato M‚ Aoki M‚ Funaki Y‚ Itoh M‚ Iwata R‚ Wong DF‚ Yanai K. Central effects of fexofenadine and cetirizine: Measurement of psychomotor performance‚ subjective sleepiness and brain histamine H1-receptor occupancy using [11C]doxepin PET. J. Clin. Pharmacol. 44(8): 890-900 (2004) |
| 173. | N. Okamura‚ Suemoto T‚ Shiomitsu T‚ Suzuki M‚ Shimadzu H‚ Akatsu H‚ Yamamoto T‚ Arai H‚ Sasaki H‚ Yanai K‚ Staufenbiel M‚ Y. Kudo‚ T. Sawada. A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain. J. Mol. Neurosci. 24: 189-197 (2004) |
| 174. | Huang YW‚ Hu WW‚ Chen Z‚ Zhang LS‚ Shen HQ‚ Timmerman H‚ Leurs R‚ Yanai K. Effect of the histamine H(3)-antagonist clobenpropit on spatial memory deficits induced by MK-801 as evaluated by radial maze in Sprague-Dawley rats. Behav Brain Res. 151(1-2): 287-93 (2004) |
| 175. | Okamura N‚ Maruyama M‚ Ebihara T‚ Matsui T‚ Nemoto M‚ Arai H‚ Sasaki H‚ Yanai K. Aspiration pneumonia and insular hypoperfusion in patients with cerebrovascular disease. J Am Geriatr Soc. 52(4):645-6 (2004) |
| 176. | Ishiwata K‚ Kawamura K‚ Wang WF‚ Tsukada H‚ Harada N‚ Mochizuki H‚ Kimura Y‚ Ishii K‚ Iwata R‚ Yanai K. Evaluation of in vivo selective binding of [11C]doxepin to histamine H1 receptors in five animal species. Nucl Med Biol. 31: 493-502 (2004) |
| 177. | N. Okamura‚ Suemoto T‚ Shimadzu H‚ Suzuki M‚ Shiomitsu T‚ Akatsu H‚ Yamamoto T‚ Staufenbiel M‚ Yanai K‚ Arai H‚ Sasaki H‚ Y. Kudo‚ T. Sawada. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci. 24(10):2535-2541 (2004) |
| 178. | H. Mochizuki‚ Y. Kimura‚ K. Ishii‚ K. Oda‚ T. Sasaki‚ M. Tashiro‚ K. Yanai‚ and K. Ishiwata. Quantitative measurement of histamine H1 receptors in human brains by PET and [11C]doxepin. Nucl Med Biol. 31(2):165-171 (2004) |
| 179. | Y.-W. Huang‚ W.-W. Hu‚ Z. Chen‚ L.-S. Zhang‚ H.-Q. Shen‚ H. Timmerman‚ R. Leurs‚ K. Yanai. Effect of the histamine H3-antagonist clobenpropit on spatial memory deficits induced by MK-801 as evaluated by radial maze in Sprague–Dawley rats. Behav. Brain Res. 151: 287–293 (2004) |
| 180. | T. Hamaguchi‚ M. Kano‚ H. Rikimaru‚ M. Kanazawa‚ M. Itoh‚ K. Yanai‚ and S. Fukudo. Brain activity during distension of the descending colon in humans. Neurogastroenterol Motil. 16(3):299-309 (2004) |
| 181. | Mizuma K‚ Ishii K‚ Barboteau S‚ Abe S‚ Yamasaki H‚ Matsuyama S‚ Sakurai E‚ Yanai K‚ Kamiya T‚ Sakai T‚ Satoh M‚ Oikawa K‚ Arakawa K‚ The elemental analysis of IgE-sensitized RBL-2H3 cells using in air micro-PIXE. International J. PIXE 14(1/2)‚ 2004:27-33. |
| 182. | J. I. Mobarakeh‚ J. W. Nalwalk‚ T. Watanabe‚ S. Sakurada‚ M. Hoffman‚ R. Leurs‚ H. Timmerman‚ I. Silos-Santiago‚ K. Yanai and L. B. Hough. Improgan antinociception does not require neuronal histamine or histamine receptors. Brain Res. 974(1-2):146-52 (2003) |
| 183. | L.-S. Zhang‚ Z. Chen‚ Y.-W. Huang ‚ W.-W. Hu‚ E. Sakurai‚ E.-Q. Wei‚ K. Yanai. Effects of endogenous histamine on seizure development of pentylenetetrazole-induced kindling in rats. Pharmacology. 69(1):27-32 (2003) |
| 184. | H. Mochizuki‚ M. Tashiro‚ M. Kano‚ Y. Sakurada‚ M. Itoh‚ K. Yanai. Imaging of central itch modulation in the human brain using positron emission tomography. Pain 105 (1-2) : 339-346 (2003) |
| 185. | M. Kano‚ S. Fukudo‚ J. Gyoba‚ K. Miyuki‚ M. Tagawa‚ H. Mochizuki‚ M. Itoh‚ M. Hongo‚ K. Yanai. Specific brain processing of emotion by facial expressions in alexithymia: a H215O-PET study. Brain 126(6):1474-1484 (2003) |
| 186. | Z. Chen‚ Z. Li‚ E. Sakurai‚ J. I. Mobarakeh‚ H. Ohtsu‚ T. Watanabe‚ T. Watanabe‚ K. Iinuma and K. Yanai. Chemical kindling induced by pentylenetetrazol in histamine H1 receptor gene knockout mice (H1KO)‚ histidine decarboxylase-deficient mice (HDC-/-) and mast cell-deficient W/Wv mice. Brain Res. 968: 162-166 (2003) |
| 187. | Tashiro M‚ Juengling FD‚ Moser E‚ Reinhardt MJ‚ Kubota K‚ Yanai K‚ Sasaki H‚ Nitzsche EU‚ Kumano H‚ Itoh M. High social desirability and prefrontal cortical activity in cancer patients: a preliminary study. Med Sci Monit. 9(4):CR119-24 (2003) |
| 188. | Y. Funaki‚ M. Kato‚ R. Iwata‚ E. Sakurai‚ E. Sakurai‚ M. Tashiro‚ T. Ido‚ and K. Yanai. Evaluation of the binding characteristics of [5-11C-methoxy]donepezil in the rat brain for in vivo visualization of acetylcholinesterase. J. Pharmacol. Sci. 91: 105-112 (2003) |
| 189. | M. Kano‚ J. Gyoba‚ M. Kamachi‚ H. Mochizuki‚ M. Hongo‚ K. Yanai. Low doses of alcohol have a selective effect on the cognition of happy facial expression. Hum. Psychopharmacol. Clin. Exp. 18(2):131-139(2003) |
| 190. | Lin L‚ Wisor J‚ Shiba T‚ Taheri S‚ Yanai K‚ Wurts S‚ Lin X‚ Vitaterna M‚ Takahashi J‚ Lovenberg TW‚ Koehl M‚ Uhl G‚ Nishino S‚ Mignot E. Measurement of hypocretin/orexin content in the mouse brain using an enzyme immunoassay: the effect of circadian time‚ age and genetic background. Peptides 23(12):2203-2211 (2002). |
| 191. | S. Sakurada‚ T. Orito‚ S. Furuta‚ H. Watanabe‚ J. I. Mobarakeh‚ K. Yanai‚ T. Watanabe‚ T. Sato‚ K. Onodera‚ C. Sakurada‚ T. Sakurada. Intrathecal histamine induces spinally mediated behavioral responses through tachykinin NK1 receptors. Pharmacol. Biochem. Behav. 74: 487-493 (2003) |
| 192. | A. J. Xu‚ Z. Chen‚ K. Yanai‚ Y. W. Huang‚ E. Q. Wei. Effect of TAK-147‚ a novel acetylcholinesterase inhibitor on spatial cognitive impairment induced by chronic cerebral hypoperfusion in rats. Neurosci. Lett. 331:33-36 (2002) |
| 193. | H. Mochizuki‚ M. Tashiro‚ M. Tagawa‚ M. Kano‚ M. Itoh‚ N. Okamura‚ T. Watanabe and K. Yanai. The effects of a sedative antihistamine‚ d-chlorpheniramine‚ on visuomotor spatial discrimination and regional brain activity as measured by positron emission tomography (PET). Hum. Psychopharmacol. Clin. Exp. 17(8):413-418 (2002) |
| 194. | Ohtsu H‚ Kuramasu A‚ Tanaka S‚ Terui T‚ Hirasawa N‚ Hara M‚ Makabe-Kobayashi Y‚ Yamada N‚ Yanai K‚ Sakurai E‚ Okada M‚ Ohuchi K‚ Ichikawa A‚ Nagy A‚ Watanabe T. Plasma extravasation induced by dietary supplemented histamine in histamine-free mice. Eur J Immunol 2002 Jun;32(6):1698-708 |
| 195. | H. Toyota‚ C. Dugovic‚ M. Koehl‚ A. D. Laposky‚ C. Weber‚ K. Ngo‚ Y. Wu‚ D. H. Lee‚ K. Yanai‚ E. Sakurai‚ T. Watanabe‚ C. Liu‚ J. Chen‚ A. J. Barbier‚ F. W. Turek‚ W.-P. Fung-Leung‚ and T. W. Lovenberg. Behavioral characterzation of mice lacking histamine H3 receptors. Mol. Pharmacol. 62: 389-397 (2002) |
| 196. | R. Iwata‚ C. Pascali‚ A. Bogni‚ S. Furumoto‚ K. Terasaki‚ K. Yanai. [18F]Fluoromethyl triflate‚ a novel and reactive [18F]fluoromethylating agent: preparation and application to the on-column preparation of [18F]fluorocholine. Applied Radiation Isotopes 57: 347-352 (2002) |
| 197. | J. I. Mobarakeh‚ S. Sakurada‚ T. Hayashi‚ T. Orito‚ K. Okuyama‚ T. Sakurada‚ A. Kuramasu‚ T. Watanabe‚ T. Watanabe and K. Yanai. Enhanced antinociception by intrathecally-administered morphine in histamine H1 receptor gene knockout mice. Neuropharmacology 42(8): 1079-1088 (2002) |
| 198. | R. Iwata‚ C. Pascali‚ A. Bogni‚ K. Yanai‚ M. Kato‚ T. Ido and K. Ishiwata. A combined loop-SPE method for the automated preparation of [11C]doxepin. J. Labelled Cpd. Radiopharm. 45: 271-280 (2002) |
| 199. | M. Tagawa‚ M. Kano‚ N. Okamura‚ M. Higuchi‚ M. Matsuda‚ Y. Mizuki‚ H. Arai‚ T. Fujii‚ S. Komemushi‚ M. Itoh‚ H. Sasaki‚ T. Watanabe‚ and K. Yanai. Differential cognitive effects of ebastine and d-chlorpheniramine in healthy subjects: Correlation between psychomotor performance and plasma concentration. Br. J. Clin. Pharmacol. 53(3): 296-304 (2002) |
| 200. | S. Sakurada‚ T. Orito‚ C. Sakurada‚ T. Sato‚ T. Hayashi‚ K. J. I. Mobarakeh‚ K. Yanai‚ K. Onodera‚ T. Watanabe‚ and T. Sakurada. Possible involvement of tachykinin NK1 and NMDA receptors in histamine-induced hyperalgesia in mice. Eur. J. Pharmacol. 434: 29-34 (2001) |
| 201. | S. Nishino‚ N. Fujiki‚ B. Ripley‚ E. Sakurai‚ M. Kato‚ T. Watanabe‚ E. Mignot and K. Yanai. Decreased brain histamine contents in hypocretin/orexin receptor 2-mutated narcoleptic dogs. Neurosci. Lett. 313: 125-128 (2001) |
| 202. | M. Tagawa‚ M. Kano‚ N. Okamura‚ M. Higuchi‚ M. Matsuda‚ Y. Mizuki‚ H. Arai‚ R. Iwata‚ T. Fujii‚ S. Komemushi‚ T. Ido‚ M. Itoh‚ H. Sasaki‚ T. Watanabe‚ and K. Yanai. Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): A comparative study of ebastine‚ a second-generation antihistamine‚ and d-chlorpheniramine‚ a classical antihistamine. Br. J. Clin. Pharmacol. 52(5): 501-509 (2001) |
| 203. | M. Endou‚ K. Yanai‚ E. Sakurai‚ S. Fukudo‚ M. Hongo and T. Watanabe. Food-deprived activity stress decreased the activity of the histaminergic neuron system in rats. Brain Res. 891: 32-41 (2001) |
| 204. | R. Iwata‚ C. Pascali‚ A. Bogni‚ Y. Miyake‚ K. Yanai‚ and T. Ido. A simple loop method for the automated preparation of [11C]raclopride from [11C]methyl triflate. Applied Radiation Isotopes 55: 17-22 (2001) |
| 205. | M. Higuchi‚ K. Yanai‚ N. Okamura‚ K. Meguro‚ H. Arai‚ M. Itoh‚ R. Iwata‚ T. Ido‚ T. Watanabe‚ and H. Sasaki. Histamine H1 receptors in patients with Alzheimer’s disease assessed by positron emission tomography (PET). Neuroscience 99: 721-729 (2000) |
| 206. | L. Z. Son‚ K. Yanai‚ J. I. Mobarakeh‚ A. Kuramasu‚ Z. Y. Li‚ E. Sakurai‚ Y. Hashimoto‚ T. Watanabe and T. Watanabe. Histamine H1 receptor-mediated inhibition of potassium-evoked release of 5-hydroxytryptamine from mice forebrains. Behav. Brain Res. 124: 113-120 (2001) |
| 207. | J. Yamakami‚ E. Sakurai‚ A. Kuramasu‚ E. Sakurai‚ K. Yanai‚ T. Watanabe and Y. Tanaka. L-Histidine decarboxylase protein and activity in rat brain microvascular endothelial cells. Inflamm. Res. 49: 231-235 (2000) |
| 208. | M. Tofukuji‚ T. Nakane‚ S. Murata‚ K. Yanai‚ M. Ohmi‚ and K. Tabayashi. Altered distribution and density of myocardial β-adrenoceptors during acute rejection in rats. Transplantation. 69: 1572-1577 (2000) |
| 209. | R. Iwata‚ G. Horváth‚ C. Pascali‚ A. Bogni‚ K. Yanai‚ Z. Kovacs‚ and T. Ido. Synthesis of 3-[1H-imidazol-4-yl]propyl4-[18F]fluorobenzyl ether ([18F]fluoroproxyfan): A potential radioligand for imaging histamine H3 receptors. J. Labelled Compd. Radiopharm. 43: 873-882 (2000) |
| 210. | M. Tagawa‚ M. Kano‚ N. Okamura‚ M. Itoh‚ E. Sakurai‚ T. Watanabe‚ and K. Yanai. Relationship between effects of alcohol on psychomotor performances and blood alcohol concentrations. Jap. J. Pharmacol. 83: 253-260 (2000) |
| 211. | M. Izumizaki‚ M. Iwase‚ H. Kimura‚ K. Yanai‚ T. Watanabe‚ T. Watanabe and I. Homma. Lack of temperature-induced polypnea in histamine H1 receptor-deficient mice‚ Neurosci. Lett. 284(3): 139-142 (2000) |
| 212. | J. I. Mobarakeh‚ S. Sakurada‚ S. Katsuyama‚ M. Kutsuwa‚ A. Kuramasu‚ Z. Y. Li‚ T. Watanabe‚ Y. Hashimoto‚ T. Watanabe and K. Yanai. Role of histamine H1 receptor in pain perception: A study of the receptor gene knockout mice. Eur. J. Pharmacol. 391: 81-89 (2000) |
| 213. | N. Okamura‚ K. Yanai‚ M. Higuchi‚ J. Sakai‚ R. Iwata‚ T. Ido‚ H. Sasaki‚ T. Watanabe‚ M. Itoh. Functional neuroimaging of cognition impaired by a classical antihistamine‚ d-chlorpheniramine. Br. J. Pharmacol. 129: 115-123 (2000) |
| 214. | R. Iwata‚ C. Pascali‚ A. Bongi‚ G. Horvath‚ Z. Kovacs‚ K. Yanai and T. Ido. A new‚ convenient method for the preparation of 4-[18F]fluorobenzyl halides. Appl. Radiat. Isot. 52: 87-92 (2000) |
| 215. | K. Yanai‚ N. Okamura‚ M. Tagawa‚ M. Itoh‚ and T. Watanabe. New findings in pharmacological effects induced by antihistamines: From PET studies to knockout mice. Clin Exp Allergy: 29 (Suppl 3): 29-36 (1999) |
| 216. | T. Morimoto‚ Y. Yamamoto‚ J. I. Mobarakeh‚ K. Yanai‚ T. Watanabe‚ T. Watanabe‚ T. Watanabe and A. Yamatodani. Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol. Behav. Vol. 67(5): 679-683 (1999) |
| 217. | H. Toyota‚ C. Ito‚ K. Yanai‚ M. Sato‚ T. Watanabe. Histamine H1 receptor binding capacities in the amygdaloid kindled rat. J. Neurochem. 72: 2177-2180 (1999) |
| 218. | T. Nakamura‚ Y. Hayashi‚ H. Watabe‚ M. Matsumoto‚ T. Horikawa‚ T. Fujiwara‚ M. Itoh and K. Yanai. Estimation of organ cumulated activities and absorbed doses on intakes of several 11C labeled radiopharmaceuticals from external measurement with thermoluminescent dosimeters. Phys. Med. Biol. 43: 389-405 (1998) |
| 219. | K. Yanai‚ L. Z. Son‚ O. Nakagawasai‚ T. Tadano‚ K. Kisara‚ T. Watanabe‚ M. Endou‚ E. Sakurai‚ and T. Watanabe. Behavioral characterization and amounts of brain monoamines and their metabolites in mice lacking histamine H1 receptors. Neuroscience 87: 479-487 (1998) |
| 220. | N. Sakai‚ E. Sakurai‚ E. Sakurai‚ K. Yanai‚ Y. Miura and T. Watanabe. Depletion of brain histamine induced by α-fluoromethylhistidine enhances radial maze performance in rats with modulation of brain amino acid levels. Life Sci. 62 (No.11): 989-994‚ 1998 |
| 221. | C. Itoh‚ K. Onodera‚ A. Yamatodani‚ K. Yanai‚ M. Sato and T. Watanabe. The effect of haloperidol on the histaminergic neuron system in the rat brain. Tohoku J. Exp. Med. 183 285-292‚ 1997 |
| 222. | Y. Ohuchi‚ H. Ohtsu‚ E. Sakurai‚ K. Yanai‚ A. Ichikawa‚ Z. Radvany‚ Z. Darvas‚ A. Falus and T. Watanabe. Induction of histidine decarboxylase in type 2 T helper lymphocyte treated with anti CD3 antibody. Inflam. Res. 47‚ Supplement1: S48-S49‚ 1998 |
| 223. | Y. Ohuchi‚ K. Yanai‚ E. Sakurai‚ H. Fukui‚ T. Yanagisawa and T. Watanabe. Histamine-induced calcium mobilization in single cultured cells expressing histamine H1 receptors: A relationship between its sensitivity and the density of H1 receptors. Int. J. Mol. Med. 1: 355-360 (1998) |
| 224. | K. Meguro‚ M. Itoh‚ K. Yanai‚ K. Takase‚ S. Yamaguchi‚ T. Ido‚ and A. Yamadori. Psychiatric wandering behaviour in dementia patients correlated with increased striatal dopamine D2 receptor as shown by [11C]YM-09151-2 and positron emission tomography. Eur. J. Neurol. 4‚ 221-226 (1997) |
| 225. | K. Yanai‚ Xiao-Lan Zhao‚ and T. Watanabe. Excitotoxic lesions of histaminergic neurons by excitatory amino acid agonists in the rat brain. Neurosci. Lett 232: 159-162 (1997). |
| 226. | H. Nakamura‚ T. Hishinuma‚ Y. Tomioka‚ S. Ishiwata‚ T. Ido‚ R. Iwata‚ Y. Funaki‚ M. Itoh‚ T. Fujiwara‚ K. Yanai‚ M. Sato‚ Y. Numachi‚ S. Yoshida and M. Mizugaki. Effect of haloperidol and cocaine pretreatments on brain distribution and kinetics of [11C]methamphetamine in methamphetamine sensitized dog: application of PET to drug pharmacokinetic study. Nucl. Med. Biol. 24‚ 165-169 (1997). |
| 227. | H. Nakamura‚ T. Hishinuma‚ Y. Tomioka‚ T. Ido‚ R. Iwata‚ Y. Funaki‚ M. Itoh‚ T. Fujiwara‚ K. Yanai‚ M. Sato‚ Y. Numachi‚ S. Yoshida and M. Mizugaki. Positron emission tomography study of the alterations in brain distribution of [11C]methamphetamine in methamphetamine-sensitized dog. Annals of the New York Academy of Sciences. 801:401-8 (1996) |
| 228. | C. Itoh‚ K. Onodera‚ K. Yanai‚ M. Sato‚ and T. Watanabe. The changes of histamine H3 receptors in methamphetamine-treated rat brain. Meth. Find. Exp. Clin. Pharmacol. 18 (Suppl. A.): 133-138 (1996) |
| 229. | X.-L. Zhao‚ K. Yanai‚ J. H. Ryu‚ Y. Hashimoto‚ H.W.M. Steinbusch‚ and T. Watanabe. Effects of unilateral vagotomy on nitric oxide synthase and histamine H3 receptors in the rat dorsal vagal complex. J. Chem. Neuroanat. 11: 221-229 (1996) |
| 230. | I. Inoue‚ K. Yanai‚ D. Kitamura‚ I. Taniuchi‚ T. Kobayashi‚ T. Watanabe‚ and T. Watanabe. Impaired locomotor activity and exploratory behaviour in mice lacking histamine H1 receptors. Proc. Natl. Acad. Sci. USA 93: 13316-13320 (1996) |
| 231. | J. H. Ryu‚ K. Yanai‚ Xiao-Lan Zhao and T. Watanabe. The effect of dopamine D1 receptor stimulation on the up-regulation of histamine H3 receptors following destruction of the ascending dopaminergic neurons. Brit. J. Pharmacol. 118: 585-592 (1996) |
| 232. | K. Ishiwata‚ K. Yanai‚ R. Iwata‚ T. Takahashi‚ J. Hatazawa‚ M. Itoh‚ K. Watabe‚ T. Watanabe and T. Ido. Analysis of plasma metabolites during human PET studies with three ligands‚ [11C]YM-09151-2‚ [11C]doxepin and [11C]pyrilamine. Tohoku J. Exp. Med. 178: 129-136 (1996) |
| 233. | K. Yanai‚ J. H. Ryu‚ T. Watanabe‚ R. Iwata‚ T. Ido‚ M. Asakura‚ R. Matsumura‚ and M. Itoh. Positron emission tomographic study on central histamine H-1 receptor occupancy in human subjects treated with epinastine. a second-generation antihistamine. Meth. Find. Exp. Clin. Pharmacol. 17: 64-69 (1995) |
| 234. | K. Yanai‚ J. H. Ryu‚ T. Watanabe‚ R. Iwata‚ T. Ido‚ Y. Sawai‚ K. Ito‚ and M. Itoh. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br. J. Pharmacol. 116 : 1649-1655 (1995) |
| 235. | N. Sakai‚ E. Sakurai‚ K. Onodera‚ K. Yanai‚ J. H. Ryu‚ T. Sasaki‚ T. Hasegawa‚ Y. Miura and T. Watanabe. Effects of L-histidine with or without thioperamide on locomotion in mice. Annals of Psychiatry Vol. 5: 215-221 (1995) |
| 236. | J. H. Ryu‚ K. Yanai‚ E. Sakurai‚ C.-Y. Kim‚ and T. Watanabe. Ontogenetic development of histamine receptor subtypes in rat brain demonstrated by quantitative autoradiography. Dev. Brain Res. 87: 101-110 (1995) |
| 237. | K. Sugimoto‚ K. Abe‚ T.-H. Lee‚ E. Sakurai‚ K. Yanai‚ K. Kogure‚ Y. Itoyama‚ T. Watanabe. Histamine depletion in brain caused by treatment with (S)α-fluoromethylhistidine enhances ishemic damage of gerbil hippocampal CA2 neurons. Brain Res. 666: 279-283 (1994) |
| 238. | N. Sakai‚ K. Yanai‚ J. H. Ryu‚ H. Nagasawa‚ T. Hasegawa‚ T. Sasaki‚ K. Kogure‚ T. Watanabe. Behavioral studies on rats with transient cerebral ischemia induced by occlusion of the middle cerebral artery. Behavioral Brain Res. 77: 181-188 (1996) |
| 239. | J. H. Ryu‚ K. Yanai‚ and T. Watanabe. Histamine H3 receptors in the striatonigral neurons are markedly increased after 6-hydroxydopamine-induced denervation of nigrostriatal dopaminergic neurons: an Autoradiographic study. Neurosci. Lett. 178: 19-22 (1994) |
| 240. | K. Yanai‚ J. H. Ryu‚ N. Sakai‚ T. Takahashi‚ R. Iwata‚ T. Ido‚ K. Murakami‚ and T. Watanabe. Binding characteristics of a histamine H3 receptor antagonist‚ [3H]S-methylthioperamide: Comparison with [3H](R)α-methylhistamine binding to rat tissues. Jap. J. Pharmacol. 65: 107-112 (1994) |
| 241. | K. Meguro‚ K. Yanai‚ N. Sakai‚ E. Sakurai‚ K. Maeyama‚ H. Fukuda‚ H. Sasaki‚ and T. Watanabe. Effects of thioperamide‚ a histamine H3 antagonist‚ on the step-through passive avoidance response in scenescence accelerated mice (SAM): Association with increased histidine decarboxylase activity. Pharmacol. Biochem. Behav. 50(3): 321-325 (1995) |
| 242. | Y. Nakagawa‚ K. Yanai‚ J. H. Ryu‚ M. Kiyosawa‚ M. Tamai‚ and T. Watanabe. Marked increase in [3H](R)a-methylhistamine binding in the superior colliculus of visually deprived rats after unilateral enucleation. Brain Res. 643: 74-80 (1994) |
| 243. | J. H. Ryu‚ K. Yanai‚ R. Iwata‚ T. Ido‚ and T. Watanabe. Heterogeneous distributions of histamine H3‚ dopamine D1 and D2 receptors demonstrated by double labeled autoradiography in rat brain. NeuroReport 5: 621-624 (1994) |
| 244. | H. Yokoyama‚ K. Iinuma‚ K. Yanai‚ T. Watanabe‚ E. Sakurai‚ K. Onodera. Proconvulsant effect of ketotifen‚ a histamine H1 antagonist‚ confirmed by the use of d-chlorpheniramine with monitoring electroencephalography. Meth. Find. Exp. Clin. Pharmacol. 15(3): 183-188 (1993) |
| 245. | K. Iinuma‚ H. Yokoyama‚ T. Otsuki‚ K. Yanai‚ T. Watanabe‚ T. Ido‚ and M. Itoh. Histamine H1 receptors in complex partial seizure. Lancet 341: 238 (1993) |
| 246. | N. Sakai‚ A. Sakurai‚ E. Sakurai‚ K. Yanai‚ K. Maeyama‚ T. Watanabe. Effects of the histamine H3 receptor ligands thioperamide and (R)-α-methylhistamine on histidine decarboxylase activity of mouse brain. Biochem. Biophys. Res. Commun. 185: 121- 126 (1992) |
| 247. | K. Yanai‚ T. Watanabe‚ R. Iwata‚ T. Ido. Receptor autoradiography with 11C and [11C]-labelled ligands visualized by imaging plates. NeuroReport. 3: 961-964 (1992) |
| 248. | K. Yanai‚ K. Maeyama‚ T. Watanabe‚ N. Nakahata and H. Nakanishi. Calcium mobilization and its desensitization by endothelins and sarafotoxin in human astrocytoma cells (132lNl): Comparison of histamine-induced calcium mobilization. Naunyn-Schmiedeberg's Arch. Pharmacol. 346: 51-56 (1992) |
| 249. | N. Sakai‚ S. Yamazaki‚ K. Onodera‚ K. Yanai‚ K. Maeyama and T. Watanabe. Effects of (S)-α-fluoromethylhistamine and (R)-α-methylhistamine on locomotor activity of WvWv mice. Pharmacol. Biochem. Behav. 46: 95-99 (1993) |
| 250. | K. Yanai‚ T. Watanabe‚ K. Megure‚ H. Yokoyama‚ I. Sato‚ K. Sasano‚ M. Itoh‚ R. Iwata‚ T. Takahashi and T. Ido. Age-dependent-decrease in Histamine H1 receptor in human brains revealed by PET. NeuroReport 3: 433-436 (1992). |
| 251. | H. Yokoyama‚ K. Onodera‚ K. Maeyama‚ K. Yanai‚ K. Iinuma‚ L. Tuomisto and T. Watanabe. Histamine levels and maximal electroshock seizure in mice: The effects of α-fluoromethylhistidine and metoprine. Naunyn-Schmiedeberg's Arch. Pharmacol. 346: 40-45 (1992) |
| 252. | R. Iwata‚ C. Pascali‚ M. Yuasa‚ K. Yanai‚ T. Takahashi‚ and T. Ido. On-line [11C]methyliodide for the automated preparation of 11C-radiopharmaccuticals. Appl. Radiat. Isot. 43: 1083-1088 (1992) |
| 253. | K. Yanai‚ T. Watanabe‚ H. Yokoyama‚ K. Meguro‚ J. Hatazawa‚ M. Itoh‚ R. Iwata‚ K. Ishiwata‚ H. Yokoyama‚ T. Takahashi‚ T. Ido. Histamine H1 receptors in human brain visualized in vivo by [11C]doxepin and positron emission tomography. Neurosci. Lett. 137(2): 145-148 (1992) |
| 254. | K. Meguro‚ K. Yanai‚ H. Yokoyama‚ A. Sakurai‚ K. Maeyama‚ T. Watanabe and T. Matsuzawa. Neurochemical studies on central histaminergic system of senescence-accelerated mice. Biog. Amines 8(5): 299-307 (1992). |
| 255. | R. Iwata‚ K. Hatano‚ K. Yanai‚ T. Takahashi‚ K. Ishiwata and T. Ido. A semiautomated synthesis system for routine preparation of [11C]YM-09151-2 and [11C]pyrilamine from [11C]methyliodide. Appl. Radiat. Isot. 42: 202-205 (1991) |
| 256. | N. Sakai‚ K. Onodera‚ K. Maeyama‚ K. Yanai and T. Watanabe. Effect of thioperamide‚ a histamine H3 receptor antagonist‚ on locomotor activity and brain histamine levels in mast cell-deficient WvWv mice. Life Sci. 48: 2397-2404 (1991) |
| 257. | V. L. Villemagne‚ R. F. Dannals‚ P. M. Sanchez-Roa‚ H. T. Ravert‚ S. Vazquez‚ A. A. Wilson‚ T. K. Natarajan‚ D. F. Wong‚ K. Yanai and H. N. Wagner‚ Jr. Imaging histamine H1 receptors in the living human brain with carbon-11-pyrilamine. J. Nucl. Med. 32: 308-311 (1991) |
| 258. | K. Yanai‚ T. Watanabe‚ J. Hatazawa‚ R. Iwata‚ K. Ishiwata‚ H. Yokoyama‚ K. Meguro‚ M. Itoh‚ T. Takahashi‚ T. Ido and T. Matsuzawa. Mapping of histamine H1 receptors in human brain by positron emission tomography with [11C]pyrilamine. J. Neurochem. 59: 128-136 (1992) |
| 259. | K. Meguro‚ J. Hatazawa‚ T. Yamaguchi‚ M. Itoh‚ T. Matsuzawa‚ S. Ono‚ H. Miyazawa‚ T. Hishinuma‚ K. Yanai‚ Y. Sekita and K. Yamada. Cerebral circulation and oxygen metabolism associated with subclinical periventricular hyperintensity as shown by magnetic resonance imaging. Ann. Neurol. 28: 378-383 (1990) |
| 260. | M. Itoh‚ J. Hatazawa‚ H. Miyazawa‚ H. Matsui‚ K. Meguro‚ K. Yanai‚ K. Kubota‚ S. Watanuki‚ T. Ido and T. Matsuzawa. Stability of cerebral blood flow and oxygen metabolism during aging. Gerontology 36: 43-48 (1990) |
| 261. | K. Yanai‚ T. Watanabe‚ J. Hatazawa‚ M. Itoh‚ K. Nunoki‚ K. Hatano‚ R. Iwata‚ K. Ishiwata‚ T. Ido and T. Matsuzawa. Visualization of histamine H1 receptors in dog brain by positron emission tomography. Neurosci. Lett. 118: 41-44 (1990) |
| 262. | K. Yanai‚ N. Yagi‚ T. Watanabe‚ M. Itoh‚ K. Ishiwata‚ T. Ido and T. Matsuzawa. Specific binding of [3H]pyrilamine to histamine H1 receptors in guinea pig brain in vivo : Determination of binding parameters by a kinetic four-compartment model. J. Neurochem. 55: 409-420 (1990) |
| 263. | K. Iinuma‚ K. Haginoya‚ K. Yanai‚ J. Hatazawa and M. Itoh. Concordance and discordance between PET images and Foci of scalp EEG. Jap. J. Psychiatr. Neurol. 43: 379-383 (1989) |
| 264. | K. Yanai‚ R. F. Dannals‚ A. A. Wilson‚ H. T. Ravert‚ U. Scheffel‚ S. Tanada and H. N. Wagner Jr. Biodistribution and radiation absorbed dose of (N-Methyl- [11C])pyrilamine: A histamine H-1 receptor imaging agent. Nucl. Med. Biol. 16: 361-363 (1989) |
| 265. | N. Fueki‚ K. Iinuma‚ A. Kojima‚ K. Haginoya‚ K. Yanai‚ K. Tada‚ T. Ido and T. Matsuzawa. Alternation of regional cerebral glucose metabolic rate for glucose at interictal and ictal stages in a case of epilepsy with electrical status epileptics during slow sleep. Jap. J. Psychiat. Neurol. 42: 611-612 (1988) |
| 266. | K. Ishiwata‚ K. Yanai‚ T. Ido‚ Y. Miura-Kanno and K. Kawashima. Synthesis and biodistribution of [11C]fludiazepam for imaging benzodiazepine receptors. Nucl. Med. Biol. 15: 365-371 (1988) |
| 267. | K. Yanai‚ R. F. Dannals‚ A. A. Wilson‚ H. T. Ravert‚ U. Scheffel‚ S. Tanada and H. N. Wagner Jr. (N-Methyl-[11C])Pyrilamine‚ a radiotracer for histamine H1 receptors: Radiochemical synthesis and biodistribution study in mice. Nucl. Med. Biol. 15: 605-610 (1988) |
| 268. | K. Iinuma‚ K. Yanai‚ T. Yanagisawa‚ N. Fueki‚ K. Tada‚ M. Itoh‚ T. Matsuzawa and T. Ido. Cerebral glucose metabolism in five patients with Lennox-Gastaut syndrome. Pediatr. Neurol. 3: 12-18 (1987) |
| 269. | K. Yanai‚ K. Iinuma‚ T. Matsuzawa‚ M. Itoh‚ S. Miyabayashi‚ K. Narisawa‚ T. Ido‚ K. Yamada and K. Tada. Cerebral glucose utilization in pediatric neurological disorders determined by positron emission tomography. Eur. J. Nucl. Med. 13: 292-296 (1987) |
| 270. | K. Yanai‚ S. Miyabayashi‚ K. Iinuma‚ K. Tada‚ H. Fukuda and T. Matsuzawa. Regional cerebral metabolic rate for glucose and cerebrospinal fluid monoamine metabolites in subacute sclerosing panencephalitis. Tohoku J. Exp. Med. 152: 103-109 (1987) |
| 271. | K. Yanai‚ K. Iinuma‚ K. Tada‚ S. Miyabayashi‚ H. Fukuda‚ M. Itoh‚ and T. Matsuzawa. Regional cerebral metabolic rate for glucose in subacute sclerosing panencepha litis. Eur. J. Pediatr. 146: 288-289 (1987) |
| 272. | K. Ishiwata‚ T. Ido‚ H. Sato‚ R. Iwata‚ K. Kawashima‚ K. Yanai‚ S. Watanuki‚ H. Ohtomo and K. Kogure. Simpilified enzymatic synthesis and biodistribution of [11C]S-adenosyl-L-methionine. Eur. J. Nucl. Med. 11: 449-452 (1986) |
| 273. | K. Yanai‚ T. Ido‚ K. Ishiwata‚ J. Hatazawa‚ T. Takahashi‚ R. Iwata and T. Matsuzawa. In vivo kinetics and displacement study of a carbon-11 Iabeled hallucinogen‚ N‚ N-[11C]dimethyltryptamine. Eur. J. Nucl. Med. 12: 141-146 (1986) |
| 274. | K. Yanai‚ T. Ido‚ K. Ishiwata‚ J. Hatazawa‚ S. Watanuki‚ T. Takahashi‚ A. Ujiie‚ M. Itoh and T. Matsuzawa. Characteristics of specific in vivo neuroleptic binding sites with 3-N-[11C]methylspiperone. Eur. J. Nucl. Med. 11: 438-443 (1986) |
| 275. | K. Ishiwata‚ T. Ido‚ K. Yanai‚ K. Kawashima‚ M. Miura‚ M. Monnma‚ S. Watanuki‚ T. Takahashi and R. Iwata. Biodistribution positron-emitting suicide inactivator of n monoamine oxidase‚ [11C]pargyline. J. Nucl. Med. 26: 630-636 (1985) |
| 276. | K. Ishiwata‚ Y. Miura‚ T. Takahashi‚ K. Kawashima‚ K. Yanai‚ M. Monnma and T. ldo. [11C]Coenzyme Q10: A new myocardial imaging tracer for positron emission tomography. Eur. J. Nucl. Med. 11: 162-165 (1985) |
| 277. | T. Takahashi‚ K. Takahashi‚ T. Ido‚ K. Yanai‚ R. Iwata‚ K. Ishiwata‚ S. Nozoe. 11C-labelling of indolealkylamine alkaroids and the comparative study of their tissue distribution. Int. J. Appl. Radiat. Isot. 36: 965-969 (1985) |
総説欧文（Reprintが必要な場合には連絡ください）
| 1. | Hattori Y‚ Ishii K‚ Yanai K‚ Endoh M. The large part German medicine has played in the development of experimental pharmacology in Japan. Naunyn Schmiedebergs Arch Pharmacol. 2023 Jan;396(1):35-42. |
|---|---|
| 2. | Kazuhiko Yanai & Maria Beatrice Passani (eds). The Functional Roles of Histamine Receptors. In Current Topics in Behavioral Neurosciences (CTBN‚ volume 59)‚ Springer 2022. ISBN: 978-3-031-16997-7 |
| 3. | Iida T‚ Yanai K‚ Yoshikawa T. Histamine and Microglia. Curr Top Behav Neurosci. 2022; 59:241-259. |
| 4. | Harada R‚ Furumoto S‚ Kudo Y‚ Yanai K‚ Villemagne VL‚ Okamura N.Imaging of Reactive Astrogliosis by Positron Emission Tomography.Front Neurosci. 2022 Feb 8;16:807435. |
| 5. | Fukudo S‚ Kano M‚ Sato Y‚ Muratsubaki T‚ Kanazawa M‚ Tashiro M‚ Yanai K. Histamine Neuroimaging in Stress-Related Disorders. Curr Top Behav Neurosci. 2022;59:113-129. |
| 6. | Yanai K‚ Yoshikawa T‚ Church MK. Efficacy and Safety of Non-brain Penetrating H1-Antihistamines for the Treatment of Allergic Diseases. Curr Top Behav Neurosci. 2022; 59:193-214. |
| 7. | Yoshikawa T‚ Nakamura T‚ Yanai K. Histaminergic Neurons in the Tuberomammillary Nucleus as a Control Centre for Wakefulness. Br J Pharmacol. 2021 Feb;178(4):750-769. |
| 8. | Yoshikawa T‚ Nakamura T‚ Yanai K. Histamine N-Methyltransferase in the Brain. Int J Mol Sci. 2019 Feb 10;20(3). pii: E737. |
| 9. | Kawauchi H‚ Yanai K‚ Wang DY‚ Itahashi K‚ Okubo K. Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties. Int J Mol Sci. 2019 Jan 8;20(1). |
| 10. | Harada R‚ Okamura N‚ Furumoto S‚ Yanai K. Imaging Protein Misfolding in the Brain Using β-Sheet Ligands. Front Neurosci. 2018 Aug 21;12:585. |
| 11. | Harada R‚ Okamura N‚ Furumoto S‚ Yanai K. Corrigendum: Imaging Protein Misfolding in the Brain Using β-Sheet Ligands. Front Neurosci. 2018 Sep 25;12:675. |
| 12. | Yanai K‚ Yoshikawa T‚ Yanai A‚ Nakamura T‚ Iida T‚ Leurs R‚ Tashiro M. The Clinical Pharmacology of Non-sedating Antihistamines. Pharmacol Ther. 2017 Oct;178:148-156. |
| 13. | Okamura N‚ Yanai K. Brain imaging: Applications of tau PET imaging. Nat Rev Neurol. 2017 Apr;13(4):197-198. PMID: 28303915 |
| 14. | Yoshikawa T and Yanai K. Histamine Clearance Through Polyspecific Transporters in the Brain. In: Handbook of Experimental Pharmacology‚ 2017;241:173-187. DOI 10.1007/164_2016_13 Springer |
| 15. | Yanai K‚ Hiraoka K‚ Kárpáti A‚ Naganuma F‚ Okamura N‚ Tashiro M‚ Nakamura T‚ and Yoshikawa T. Histamine H1 Receptor Occupancy in Human Brain. In: Histamine Receptors: Preclinical and Clinical Aspects (Eds. Blandina P and Passani BM. ISBN: 978-3-319-40306-9) Springer 2016: pp311-325 |
| 16. | Harada R‚ Okamura N‚ Furumoto S‚ Tago T‚ Yanai K‚ Arai H‚ Kudo Y. Characteristics of Tau and Its Ligands in PET Imaging. Biomolecules. 2016 Jan 6;6(1). pii: E7. Review. |
| 17. | Okamura N‚ Harada R‚ Furukawa K‚ Furumoto S‚ Tago T‚ Yanai K‚ Arai H‚ Kudo Y. Advances in the development of tau PET radiotracers and their clinical applications. Ageing Res Rev. 2016 Jan 21. pii: S1568-1637(15)30045-3. |
| 18. | Jáuregui I‚ Ramaekers JG‚ Yanai K‚ Farré M‚ Redondo E‚ Valiente R‚ Labeaga L. Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving. Expert Opin Drug Saf. 2015 Nov 16:1-10. |
| 19. | Okamura N‚ Harada R‚ Furumoto S‚ Arai H‚ Yanai K‚ Kudo Y. Tau PET imaging in Alzheimer's disease. Curr Neurol Neurosci Rep. 2014 Nov;14(11):500. |
| 20. | Yanai K‚ Rogala B‚ Chugh K‚ Paraskakis E‚ Pampura AN‚ Boev R. Safety considerations in the management of allergic diseases: focus on antihistamines. Current Medical Research & Opinion Vol. 28 (4) :1–20 (2012) |
| 21. | Yanai K. Anticholinergic activity of antihistamines. Clin Neurophysiol. 123(4):633-4 (2012 |
| 22. | Yanai K‚ Zhang D‚ Tashiro M‚ Yoshikawa T‚ Naganuma F‚ Harada R‚ Nakamura T‚ Shibuya K‚ Okamura N. Positron emission tomography evaluation of sedative properties of antihistamines. Expert Opinion on Drug Safety 2011 Jul;10(4):613-22. |
| 23. | Okamura N‚ Yanai K. Florbetapir (18F)‚ a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease. IDrugs. 2010;13(12): 890-899. |
| 24. | Okamura N‚ Fodero-Tavoletti MT‚ Kudo Y‚ Rowe CC‚ Furumoto S‚ Arai H‚ Masters CL‚ Yanai K‚ Villemagne VL. Advances in molecular imaging for the diagnosis of dementia. Expert Opin. Med. Diagn. 2009; 3: 705-716. |
| 25. | Okamura N‚ Furumoto S‚ Arai H‚ Iwata R‚ Yanai K‚ Kudo Y. Imaging amyloid pathology in the living brain. Curr Med Imaging Rev. 2008; 4:56-62. |
| 26. | Furumoto S‚ Okamura N‚ Iwata R‚ Yanai K‚ Arai H‚ Kudo Y. Recent advances in the development of amyloid imaging agents. Curr Top Med Chem. 2007;7(18):1773-89. |
| 27. | Yanai K‚ Tashiro M. The physiological and pathophysiological roles of neuronal histamine: An insight from human PET studies. Pharmacology & Therapeutics113: 1–15 (2007) |
| 28. | Maeyama K‚ Yanai K. Recent advances in molecular pharmacology of the histamine system: preface. J Pharmacol Sci. 101(1):1-2 (2006) |
| 29. | Kuramasu A‚ Sukegawa J‚ Yanagisawa T‚ Yanai K. Recent advances in molecular pharmacology of the histamine systems: roles of C-terminal tails of histamine receptors. J Pharmacol Sci. 2006; 101(1):7-11. |
| 30. | Seeman P‚ Schwarz J‚ Chen JF‚ Szechtman H‚ Perreault M‚ McKnight GS‚ Roder JC‚ Quirion R‚ Boksa P‚ Srivastava LK‚ Yanai K‚ Weinshenker D‚ Sumiyoshi T. Psychosis pathways converge via D2(High) dopamine receptors. Synapse 60(4):319-346 (2006) |
| 31. | Ennis M‚ Masini E‚ Sturman G‚ Yanai K. Honorary membership of the European Histamine Research Society (EHRS). Inflamm Res. 2006 Apr;55(Supplement 1):S03-S04. |
| 32. | S. T. Holgate‚ Canonica GW‚ Simons F Estelle R‚ Taglialatela M‚ Tharp M‚ TimmermanH‚ Yanai K. Consensus group on new generation antihistamines (conga): present status and recommendations. This Consensus Group was convened under the auspices of the British Society for Allergy and Clinical Immunology. Clin Exp Allergy. 2003 33(9):1305-1324. |
| 33. | K. Yanai and T. Watanabe. Histamine as a neurotransmitter in the central nervous system. In: A. Falus‚ N. Grossman & Zs. Darvas eds. Histamine : Biology and Medical aspects. 2004: 251-263 |
| 34. | T. Watanabe and K. Yanai. Studies on functional roles of the histaminergic neuron system by using pharmacological agents‚ knockout mice and positron emission tomography. Tohoku. J. Exp. Med. 195: 197-217 (2001) |
| 35. | H. Fukui and K. Yanai. Histamine Receptors. In Methods in neurotransmitter and neuropeptide research (S.H. Parvez‚ M. Naoi‚ T. Nagatsu‚ S. Parvetz (eds)) Chapter 6 141-188 1993 Elsevier Science Publishers B.V. Amsterdam |
| 36. | T. Watanabe and K. Yanai. Most recent advance in histamine research. In Histaminergic Neurons: Morphology and Functions (T. Watanabe and H. Wada eds.)‚ pp403-405‚ CRC Press‚ Boca Raton‚ 1991 |
| 37. | K. Yanai‚ T. Watanabe‚ M. Itoh‚ R. Iwata‚ J. Hatazawa and T. Ido. Imaging of Neurotransmitter receptors in the living human brain by positron emission tomography: its methodology and prespective. In Anuario Psiquiatrico 2: 63-76 (1991) |
その他欧文（プロシーディング欧文等、単行本など）
| 1. | Yanai K‚ Okamura N‚ Iwata R‚ Tashiro M. Molecular imaging and its application to drug developement at Tohoku University. In “Nano-Biomedical Engineering 2009: Proceedings of the Tohoku University Global Centre of Excellence Programme” (Editor: Takami Yamaguchi). pp175- 183. Imperial College Press 2009 |
|---|---|
| 2. | Sakurai E‚ Sakurai E‚ Watanabe T‚ Yanai K. Uptake of L-histidine and histamine biosynthesis at the blood-brain barrier. Inflamm Res. 2009 Apr;58 Suppl 1:34-5. |
| 3. | Sakurai E‚ Kuramasu A‚ Watanabe T‚ Yanai K. Multiple histamine receptor gene knockout mice and their phenotypes. Inflamm Res. 2009 Apr;58 Suppl 1:41-2. |
| 4. | Yanai K‚ Dai H‚ Sakurai E‚ Watanabe T. The roles of histamine H1 receptors on cognition. Inflamm Res. 2008; 57 Suppl 1:S39-40. |
| 5. | Dai H‚ Okuda H‚ Iwabuchi K‚ Sakurai E‚ Chen Z‚ Kato M‚ Iiinuma K and Yanai K. (2004). Social isolation stress significantly enhanced the disruption of prepulse inhibition in repeatedly methamphetamine-treated mice. Annals of the New York Academy of Sciences. 1025: 257-266 (2004) |
| 6. | Iwabuchi K‚ Kubota Y‚ Ito C‚ Watanabe T‚ Yanai K. 2004. Metamphetamine and Brain Histamine: A Study Using Histamine-Related Genes Knockout Mice. Annals of the New York Academy of Sciences. 1025: 129-134 (2004) |
| 7. | Jin CL‚ Sakurai E‚ Kiso Y‚ Luo JH‚ Yanai K‚ Chen Z. Influence of low dietary histamine on seizure development of chemical kindling induced by pentylenetetrazol in rats.‚ Acta Pharmacol Sin. 2005 Apr;26(4):423-7. |
| 8. | Hu WW‚ Chen Z‚ Xu LS‚ Jin CL‚ Sakurai E‚ Yanai K. [Effect of alahistidine on brain histamine content and seizure development] Zhejiang Da Xue Xue Bao Yi Xue Ban. 2004 May;33(3):197-200. Chinese. (2004) |
| 9. | Tashiro M‚ Mochizuki H‚ Iwabuchi K‚ Sakurada Y‚ Itoh M‚ Watanabe T‚ Yanai K. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci. 2002; 72(4-5):409-14. |
| 10. | Takehiko Watanabe‚ Henk Timmerman and Kazuhiko Yanai (Eds). Histamine Research in the New Millennium. Proceedings of the International Sendai Histamine Symposium. Excerpta Medica International Congress Series 1224. pp1-521‚ Amsterdam‚ Elsevier Science B.V. |
| 11. | K. Yanai‚ L. Z. Son‚ M. Endou‚ E. Sakurai‚ and T. Watanabe. Targeting disruption of histamine H1 receptors in mice: Behavioral and neurochemical characterization. Proceeding of 2 nd. International Symposium on Membrane Receptor-Signaling System. Life Sci. 62 (17/18): 1607-1610 (1998) |
| 12. | M. Higuchi‚ M. Itoh‚ K. Yanai‚ N. Okamura‚ A. Yamaki‚ T. Ido‚ H. Arai and H. Sasaki. Brain mapping of the effects of aging on histamine H1 receptors in humans: A PET study with [11C]doxepin. Quantitative functional brain imaging with positron emission tomography. (Eds. R. Carson‚ M. Daube-Witherspoon and P. Herscovitch)‚ Academic Press‚ San Diego‚ CA‚ USA Chapter 31‚ pp 207-214‚ 1998 |
| 13. | I. Inoue‚ K. Yanai‚ T. Watanabe‚ and T. Watanabe. Analysis of histamine H1 receptor deficient mice: Role in locomotor activity and anaphylaxis. IN: Gene targeting and new developments in neurobiology. Tanigucgi Symposia on Brain Sciences No. 19‚ pp. 139-149‚ 1996 |
| 14. | T. Fujiwara‚ M. Mejia‚ M. Itoh‚ K. Yanai‚ K. Meguro‚ H.Sasaki‚ S. Ono‚ H. Itoh‚ H.Fukuda‚ R. Iwata‚ T. Ido‚ H. Watabe‚ V.J.Cunnigham‚ J. Ashburner‚ and T. Jones. Quantitative imaging of [11C]benztropine in the human brain with graphical analysis and spectral analysis. In Quantification of human function using PET (Eds. R. Myers‚ V. Cunnigham‚ D. Bailey‚ & T. Jones). pp317-320‚ Academic Press‚ San Diego‚ California‚ 1996 |
| 15. | K. Yanai‚ J. H. Ryu‚ T. Watanabe‚ R. Iwata‚ and T. Ido. Receptor autoradiography with 11C- and 3H-Iabeled ligands visualized by phosphor imaging plates. Radioautoradiography in Medicine. Proceedings of the 4th International Symposium on Radioautography. (T. Nagata ed.) p238-242. Shinshu University Press 1994. |
| 16. | K. Yanai‚ J. H. Ryu‚ M. Itoh‚ R. Iwata‚ T. Takahashi‚ T. Ido and T. Watanabe. Labelling of histamine H1‚ H2‚ and H3 antagonists with carbon-11: Radiopharmaceuticals for PET studies. Proceedings of the second international symposium on clinical PET in oncology. (T. Matsuzawa ed.) p367-370. World Scientific Singapore 1994 |
| 17. | H. Yokoyama‚ K. Yanai‚ K. Iinuma‚ T. Watanabe‚ M. Itoh‚ T. Fujiwara‚ R. Iwata‚ T. Takahashi‚ and T. Ido. Mapping of histamine H1-receptors in patients with complex partial seizure with PET and 11C-doxepin. In Quantification of Brain Function: Tracer kinetics and Image Analysis in Brain PET (K. Uemura eds) p297-301 1993 Elsevier Science Publishers B.V. Amsterdam |
| 18. | K. Yanai‚ T. Watanabe‚ M. Itoh‚ and T. Ido. Imaging of neurotransmitter receptors in the living human brain by positron emission tomography (PET). The Proceeding of the First International Congress on Vitamine and Biofactors in Life Science. Sept. 20‚ 1991‚ Kobe pp581-584 |
| 19. | K. Yanai‚ T. Watanabe‚ M. Itoh‚ J. Hatazawa‚ R. Iwata and T. Ido. Labeling of histamine H1 receptors in vivo: A compartment model analysis and positron emission tomography. in New Prospective in Histamine Research (H. Timmerman and H. van der Goot‚ Eds.)‚ pp 417-422‚ Brinkhauser‚ Basel‚ Boston‚ Berlin‚ 1991 |
総説和文（Reprintが必要な場合には連絡ください）
| 1. | 谷内一彦 抗ヒスタミン薬の薬理作用 アロス エルゴン Vol.2 (no.2):646-651‚ 2022 |
|---|---|
| 2. | 谷内一彦、吉川雄朗 ヒスタミンH1受容体拮抗薬による眠気と鎮静作用発生メカニズム Visual dermatology 21: 262-265‚ 2022 |
| 3. | 中村正帆、谷内一彦。アレルギー性鼻炎の第一選択薬としての非鎮静性抗ヒスタミン薬。Progress in Medicine、40:1157-1164‚ 2020 |
| 4. | 原田龍一、盛戸貴裕、谷内一彦。タンパク質医薬品開発のためのポジトロン放出核種標識タンパク質。日本薬理学会雑誌 155 印刷中 2020 |
| 5. | 谷内一彦。薬理作用から見た理想的な抗ヒスタミン薬治療。耳鼻咽喉科学会誌 123：196-204‚ 2020 |
| 6. | 原田龍一、盛戸貴裕、谷内一彦。ポジトロン放出核種標識タンパク質の新規合成方法の開発。バイオインダストリーVol.36 No.12: p46-54‚ 2019 |
| 7. | 谷内一彦。小児における抗ヒスタミン薬の選択について考える。小児耳 2018; 39 (3): 275–282 |
| 8. | 吉川 雄朗、中村正帆、谷内 一彦。 新規遺伝子ノックアウトマウスを用いた脳内ヒスタミンクリアランス系の解明 日本薬理学会雑誌 152:16-20‚2018 |
| 9. | 原田 龍一、岡村 信行、古本 祥三、谷内 一彦。PETを用いた脳タンパク質の可視化 細胞：特集「脳タンパク質老化と認知症制御」Vol60(6):295-298‚ 2018 |
| 10. | 岡村信行、原田龍一、古本祥三、中村正帆、谷内一彦、工藤幸司 アルツハイマー病理を標的とした分子イメージングプローブの開発 日本薬理学会雑誌 150:172-176‚ 2017 |
| 11. | 谷内一彦、中村正帆 抗ヒスタミン薬と抗アレルギー薬の違いは？質疑応答：日本医事新報No.4877 (2017年10月14日発行) P.62-64 |
| 12. | 谷内一彦、中村正帆 抗ヒスタミン薬の疼痛抑制機序は？質疑応答：日本医事新報No.4858 (2017年06月03日発行) P.63-65 |
| 13. | 谷内一彦、谷内亜衣、中村正帆、吉川雄朗 臨床薬理学からみた非鎮静性抗ヒスタミン薬 アレルギーの臨床 2017: 37(1)‚ 35-39 |
| 14. | 原田 龍一、岡村 信行、古本 祥三、工藤 幸司、谷内 一彦。タウイメージング：18F−THK5351 最新醫學 71巻3月増刊号(通巻907号）特集 認知症 p.595-600 |
| 15. | 岡村信行，原田龍一，工藤幸司，谷内一彦 アミロイドイメージング・タウイメージングの現状と展望。日本薬理学会雑誌 146:144-149‚ 2015 |
| 16. | 福土審、金澤素、鹿野理子、森下城、村椿智彦、田中由佳理、田代学、谷内一彦 脳腸相関を画像化する：PET G.I.Research 2015‚ 23(2):120-123 |
| 17. | 中村正帆、吉川雄朗、谷内一彦 抗ヒスタミン薬開発の歴史 Dermatology Today Vol.16 2014 pp14-17 |
| 18. | 三浦大和、飯田智光、長沼史登、中村正帆、吉川雄朗、谷内一彦 ヒスタミンと睡眠との関わり：ヒスタミン神経系の覚醒と睡眠 Progress in Medicine 2013；33(12)‚2589-2594 |
| 19. | 飯田智光、三浦 大和、長沼史登、中村正帆、吉川雄朗、谷内一彦 ヒスタミンの生理作用：“善玉”としてのヒスタミン 皮膚アレルギーフロンティア vol.11: 65-70‚ 2013 |
| 20. | 中村正帆、長沼史登、谷内一彦、吉川雄朗 非鎮静性抗ヒスタミン薬の薬理学的特徴 アレルギーの臨床33: 22-26 (2013) |
| 21. | 長沼史登、谷内一彦 「抗ヒスタミン薬はなぜ眠気を誘発するのか？」「数多く存在する抗ヒスタミン薬はどのように分類して考えればよいのか？」「抗ヒスタミン薬同士の併用は意味があるのか？」抗ヒスタミン薬：達人の処方箋 メディカルレビュー社 総ぺ―ジ数301、2013 |
| 22. | 古本祥三、田代学、岩田錬、谷内一彦。日本をリードするPET橋渡し研究拠点：東北大学サイクロトロン・ラジオアイソトープセンター PET Journal 18: 4-6‚ 2012 |
| 23. | 宮地良樹、岡本美孝、谷内一彦（編・著）ファーマーナビゲーター：抗ヒスタミン薬編 メディカルレビュー社 総ぺ―ジ数300、2012 |
| 24. | 谷内一彦 臨床研究とGCP：最近の動向 日本臨床増刊号 認知症学（下）vol69(Suppl10)‚ pp16-21‚ 2011 |
| 25. | 古本祥三、谷内一彦 薬物動態評価のPET分子イメージング 特集「分子イメージング薬剤の標的選択的動態制御」 Drug Delivery System 26(4): 401-409‚ 2011 |
| 26. | 谷内一彦 臨床試験と倫理：最近の動向 ペインクリニック 32(7):1045-1051‚ 2011 |
| 27. | 谷内一彦、長沼史登 第二世代抗ヒスタミン薬の薬理学的特徴 日本医事新報 4547: 57-59‚ 2011 |
| 28. | 谷内一彦、長沼史登、中村正帆、吉川雄朗 ヒスタミン受容体を理解する Dermatology Today 4: 4-9 (2011) |
| 29. | 岡村信行、谷内一彦、工藤幸司 アルツハイマー病における脳アミロイドの画像化 MB Med Reha 132: 131-138 (2011) |
| 30. | 谷内一彦、吉川雄朗、古本祥三 画像バイオマーカーとしての分子イメージングの利用：分子イメージングによる受容体占拠率の解析 「創薬研究への分子イメージング応用」遺伝子MOOK18 pp133-139 佐治英郎編集 2010 メデイカルドゥ |
| 31. | 谷内一彦 特集に寄せて「ヒスタミンH1受容体拮抗薬の臨床」アレルギーの臨床 2010：30巻 Ｐ１２３６ 北隆館 |
| 32. | 荻野 敏、谷内一彦 インペアード・パフォーマンスゼロプロジェクトに期待される活動：リスク＆ベネフィットを考慮した花粉症治療に向けて 診療と新薬 47(8)：751-760 (2010) |
| 33. | 室田浩之、片山一郎、谷内一彦 かゆみを伴う皮膚疾患における抗ヒスタミン薬の選択：薬剤のパフォーマンスに及ぼす影響を考慮して 診療と新薬 47(9)：964-973 (2010) |
| 34. | 谷内一彦 臨床研究の倫理と利益相反 最新クリニカルPET 米倉義晴編 先端医療技術研究所 pp 227-231 (2010) |
| 35. | 谷内一彦、田代学、古本祥三、吉川雄朗、岡村信行 ヒスタミンH1受容体占拠率による脳内移行性評価 遺伝子MOOK別冊「創薬技術の革新：マイクロドーズからPET分子イメージングへの新展開」p147-152 (2010) 杉山雄一、山下伸二、栗原千絵子編集 メデイカルドウ |
| 36. | 谷内一彦、田代学 ヒスタミンと精神疾患 専門医のための精神科臨床リュミエール16 神庭重信、加藤忠史編集 p228-230 (2010) 中山書店 |
| 37. | 中村正帆、吉川雄朗、谷内一彦 脳機能を標的とした新しい痒み治療戦略：痒みイメージング研究の視点から 特集「脳とアレルギー」アレルギー・免疫17(10): 1868-1873 (2010) |
| 38. | 谷内一彦 CONGAコンセンサスに準じたレボセチリジンの評価 特集「新規抗ヒスタミン薬レボセチリジン」 医薬ジャーナル 46(10): 2506-2511 (2010) |
| 39. | 片山一郎、谷内一彦、Christpher Alford、Erwin Gelfand、Ian Hindmarch、幸野健、大久保公裕、Torsten Zuberbier. 抗ヒスタミン薬の選択：最適な治療の視点から アレルギー・免疫 17: 456-468 (2010) |
| 40. | 谷内一彦、赤池紀生 ヒスタミンH1、H2受容体遺伝子欠損マウスの作成と意義 生体の科学 60(5):442-443 (2009) |
| 41. | 谷内一彦、吉川雄朗 抗ヒスタミン薬と認知機能：dimebonはアルツハイマー病の認知機能を改善する 最近の話題 日薬理誌134：235 (2009) |
| 42. | 谷内一彦、田代学、千葉真 抗ヒスタミン薬による運転能力障害に対する認識 鼻アレルギーフロンティア9(1): 58-64 (2009) |
| 43. | 熊谷雄治、Ian Hindmarch、谷内一彦 抗ヒスタミン薬の新分類：Not Impairing antihistamine (NIaH)とImpairing antihistamine (IaH) 診断と治療 97(1): 177-186 (2009) |
| 44. | 栗原千絵子、福島芳子、稲野彰洋、谷内一彦 人を対象とする研究に関する倫理規定・標準業務手順書について：分子イメージング臨床研究及びトランスレーショナルリサーチの推進基盤 臨床評価 36(3): 747-784 (2009) |
| 45. | 谷内一彦 睡眠とヒスタミンのかかわりを探る 特集「睡眠と生活習慣病のかかわりを探る」 Life Style Medicine 3(3): 234-240 (2009) |
| 46. | 谷内一彦、櫻井映子、岡村信行、倉増敦朗 「他領域からのトピックス」抗ヒスタミン薬の薬理学 日本耳鼻咽喉科学会会報112:99-103 (2009) |
| 47. | 谷内一彦、田代学、岡村信行 中枢に移行しない第二世代抗ヒスタミン薬：PETによる脳内移行性に関する研究 西日本皮膚科 71巻1号：3-6 (2009) |
| 48. | 谷内一彦、田代学 インペアード・パフォーマンス：国際標準に基づく抗ヒスタミン薬の使用法 医薬ジャーナル 45:687-693 (2009) |
| 49. | 谷内一彦、須原哲也 序にかえて「脳の核医学分子イメージング」 臨床放射線53(7): 845-848 (2008) |
| 50. | 谷内一彦、田代学 抗ヒスタミン薬のヒスタミンH1拮抗作用とインペアード・パフォーマンス 臨床免疫・アレルギー科 50(1):46-51‚ 2008 |
| 51. | 岡村信行，古本祥三，工藤幸司，谷内一彦．アルツハイマー病．日本臨床，65(2):320-325‚ 2007. |
| 52. | 岡村信行，谷内一彦．脳の分子イメージング アミロイドイメージング．遺伝子医学MOOK ますます広がる分子イメージング技術，p220-224. 株式会社メディカルドゥ |
| 53. | 岡村信行，谷内一彦．アミロイドイメージング．老年精神医学雑誌，18(8):855-860‚ 2007. |
| 54. | 岡村信行，谷内一彦，古川勝敏，荒井啓行，工藤幸司．アミロイドイメージング PET，日本臨床，66 Suppl 1:288-292‚ 2008. |
| 55. | 川島眞、江藤隆史、江畑俊哉、大谷道輝、片山一朗、幸野健、瀧川雅浩、田邉昇、中川秀巳、原田昭太郎、古川福実、森川昭広、谷内一彦 アレルギー性皮膚疾患におけるエビデンスに基づいた抗ヒスタミン薬の選択 臨床皮膚科 62(1): 8-15 (2008) |
| 56. | 谷内一彦、岡村信行、田代学 脳内に移行する抗ヒスタミン薬の小児に与える影響 小児科 48(10): 1435-1443 (2007) |
| 57. | 鈴木美穂、岡村信行、谷内一彦 PETによる分子・機能イメージングを組み合わせた脳機能研究 認知神経科学 9(1): 62-65 (2007) |
| 58. | 谷内一彦、加藤元久 抗アレルギー薬、抗精神病薬、抗うつ薬のヒスタミンH1拮抗作用と認知機能 脳21 解説「脳とくすり」10(1): 85-90 (2007) |
| 59. | 岡村信行、谷内一彦、工藤幸司 アミロイドイメージングの進歩 Dementia Japan 20: 216-225 (2006) |
| 60. | 田代学、谷内一彦 ヒスタミン受容体の分子イメージング BRAIN AND NERVE 59(3): 221-231 (2007) |
| 61. | 岡村信行、古本祥三、工藤幸司、谷内一彦 脳の分子イメージング：アルツハイマー病 特集「分子イメージング」日本臨床65(2): 320-326 (2007) |
| 62. | 馬場廣太郎、谷内一彦 学童期のアレルギー性鼻炎患者に対する抗ヒスタミン薬の使用 新薬と臨床55(11): 1683-1691‚ 2006 |
| 63. | 中川秀己、谷内一彦 学童期のアトピー性皮膚炎患者に対する抗ヒスタミン薬の使用 アレルギーの臨床 26(11): 945-952‚ 2006 |
| 64. | 奥田友宏、谷内一彦 脳内ヒスタミン Clinical Neuroscience 24(8)‚ 848-849 (2006) |
| 65. | 岡村信行、谷内一彦 アルツハイマー病のβアミロイドイメージング 特集「分子イメージングと認知症」Cognition and Dementia 5(3): 192-198 (2006) |
| 66. | 奥田友宏、谷内一彦 ストレスと覚醒剤依存形成 医学のあゆみ 271‚ 1161-1166 (2006) |
| 67. | 望月秀紀、谷内一彦 痒みに関する脳機能イメージング研究の展開 日薬理誌 127，147〜150（2006） |
| 68. | 鹿野理子、谷内一彦 ストレス関連障害の脳イメージング 特集「ストレスに耐える脳、耐えられない脳」脳２１ 9(1): 32-36 (2006) |
| 69. | 岡村信行、谷内一彦 PETを用いた脳機能の分子イメージング 日薬理誌 126: 347-352 (2005) |
| 70. | 櫻井映子、田代学、谷内一彦 食物アレルギー治療におけるヒスタミン受容体アンタゴニスト カレントテラピー 23(11): 66-71 (2005) |
| 71. | 谷内一彦、岡村信行、倉増敦朗 中枢ヒスタミン神経の解剖とその機能 アレルギー・免疫 Vol. 12(2): 94-99 (2005) |
| 72. | 田代学、鹿野理子、福土審、谷内一彦 ヒトの情動メカニズムにせまる脳イメージング研究の進歩 日本薬理学会雑誌 Vol. 125(2): 88-96 (2005) |
| 73. | 田代学、櫻田幽美子、谷内一彦 脳イメージングの基礎と応用 ペインクリニック Vol. 26(1): 53-62 (2005) |
| 74. | 田代学、谷内一彦、望月秀紀、Jalal Izadi Mobarakeh、櫻田忍 痛みとかゆみの受容におけるヒスタミン受容体の役割 ペインクリニック Vol. 25(11): 1495-1505 (2004) |
| 75. | 谷内一彦 アレルギー相談室Q＆A アレルギーの臨床 24(11): 911 (2004) |
| 76. | 谷内一彦 理想的な抗ヒスタミン薬の基準とCONGA会議 Progress in Medicine 24(1) : 262-267 (2004) |
| 77. | 谷内一彦、田代学、岡村信行 フェキソフェナジン：中枢に移行しない第２世代抗ヒスタミン薬 Molecular Medicine 41 (8) : 1008-1015 (2004) |
| 78. | 望月秀紀、田代学、谷内一彦 中枢性かゆみの機序 特集かゆみ 総合臨床 53巻(5)：1645-1650（2004） |
| 79. | 谷内一彦、田代学 臨床薬理試験における非侵襲的生体機能評価法の位置づけ：PETによる機能評価19巻（12号）：1354-1367（2003） |
| 80. | 谷内一彦、Jalal Izadi Mobarakeh、倉増敦朗、櫻田忍 ノックアウトマウス研究から明らかにされる痛み受容におけるヒスタミン受容体の役割。日薬理誌 122: 391-399 (2003) |
| 81. | 倉増敦朗、谷内一彦 神経系におけるヒスタミン受容体の役割。遺伝子医学 7巻204-208（2003） |
| 82. | 田代学、谷内一彦、伊藤正敏 精神症状発現に関するニューロイメージング研究。医学のあゆみ Vol. 205(12): 926-930（2003） |
| 83. | 谷内一彦、田代学、岡村信行、倉増敦朗 抗ヒスタミン薬の有効性と安全性の新しいエビデンス。アレルギー科 15(6): 517-523 (2003) |
| 84. | 谷内一彦 抗ヒスタミン薬の最新のトピックス：有効性と安全性の新しいエビデンス。鼻アレルギーフロンティア 3 (2): 72-78 (2003) |
| 85. | 谷内一彦、岩渕健太郎、鹿野理子 精神疾患におけるヒスタミン神経系の役割。医学のあゆみ 204：262-264（2003） |
| 86. | 遠藤雅俊、櫻井映子、渡邉建彦、谷内一彦 ヒスタミンとストレス応答。Clinical Neuroscience 21(2): 180-183 (2003) |
| 87. | 谷内一彦、田代学 眠気とインペアード・パフォーマンス 医薬ジャナール 39：156-162 (2003) |
| 88. | 谷内一彦、田代学、望月秀紀、櫻田幽美子 抗ヒスタミン薬の中枢作用 アレルギーの臨床22(13): 71-76 (2002) |
| 89. | 岩淵健太郎、佐藤光源、谷内一彦 精神薬物療法と脳画像解析 精神医学44(11):1181-1187(2002) |
| 90. | 田代学、谷内一彦 抗ヒスタミン薬の画像研究から明らかにされるH1受容体の中枢薬理作用。アレルギー科13(5):434-442(2002) |
| 91. | 谷内一彦 花粉症の薬物治療法と患者のQOL：眠気とインペアード・パフォーマンス 朝日メヂィカル別冊 平成14年2月 |
| 92. | 谷内一彦、望月秀紀、田代 学。眠気の神経機構。Clinical Neuroscience 20(4): 398-401 (2002) |
| 93. | 谷内一彦。眠気とインペアード・パフオーマンス〜第二世代抗ヒスタミン薬で注意したい副作用〜 鼻アレルギーフロンティア 1(3): 72-76 (2001) |
| 94. | 谷内一彦。抗ヒスタミン薬による眠気とインペアード・パフオーマンス 鼻アレルギーフロンティア 1(4): 60-63 (2001) |
| 95. | 谷内一彦、田代学。ヒスタミン神経系と眠気。Clinical Neuroscience 19巻10号: 1179-1182‚ 2001 |
| 96. | 谷内一彦、田川正秋、望月秀紀。放射性リガンド開発と創薬。脳の科学。特集「神経伝達機能イメージングの新たなる展開」23: 191-197‚ 2001 |
| 97. | 田川正秋、谷内一彦。PETによる抗ヒスタミン薬の鎮静作用発症メカニズムの解明。医学のあゆみ。特集：７回膜貫通型受容体と疾患・創薬研究。171-176‚ 2001 |
| 98. | 谷内一彦、岩田錬。PETを用いた神経活動の画像化の将来像：ヒスタミン神経系を例に。脳の動態を見る：記憶とその障害の分子機構（高田明和、加藤武、中原大一郎、野村正彦編集）pp126−133 医学書院 2001年4月15日 |
| 99. | 谷内一彦。抗ヒスタミン薬の眠気と認知機能障害。Asahi Medical別冊2001年2月1日号 |
| 100. | 田川正秋、谷内一彦、渡邉建彦。抗ヒスタミン薬による鎮静作用発症メカニズムの解明：PETを用いたエバスチンのヒト脳内移行の評価。Prog. Med.‚ 21‚ 2882-2886 (2001) |
| 101. | 谷内一彦、田川正秋。ポジトロンCTによる脳神経薬理解析研究。日本臨床「現代医学の焦点」58巻第10号：193-201(2000) |
| 102. | 谷内一彦、Jalal Izadi Mobarakeh、鹿野理子、望月秀紀、櫻田忍。遺伝子欠損マウスを用いての疼痛制御機構の研究。痛みの受容におけるヒスタミンの役割：H1受容体遺伝子ノックアウトマウスを用いた研究。P183-191「オピオイドの基礎と臨床」ミクス出版2000年 |
| 103. | 谷内一彦、田川正秋、岡村信行。ポジトロン・エミッション・トモグラフィー（PET）による抗ヒスタミン薬の脳内移行と認知機能障害のイメージング。医学のあゆみ 別冊「ヒスタミン研究の最近の進歩」pp.101-106 (2000) |
| 104. | 谷内一彦、田川正秋、岡村信行。PETによる眠気と認知機能障害発生メカニズム研究：抗ヒスタミン薬を例に。月刊薬事 42: 587-591 (2000) |
| 105. | 谷内一彦。痴呆症の治療と予防。セロトニン、ヒスタミン系薬剤。特集「アルツハイマー病と異常蛋白沈着による痴呆症をめぐる最近の話題」Pharma Medica 18: 73-79 (2000) |
| 106. | 谷内一彦。ＰＥＴを用いたヒト脳の神経薬理学的研究。日本薬理学会雑誌、114: 169-178 (1999) |
| 107. | 谷内一彦。渡邉建彦、岡村信行、伊藤正敏。ＰＥＴを用いたヒト脳の神経薬理学的研究と創薬。日本薬理学会雑誌、112、補冊1、48p-52p、１９９８年 |
| 108. | 谷内一彦。脳における受容体の観察。特集「ヒト脳・脊髄の働きを見る」 Brain Medical Vol10(No.2) 63-70、1998年 |
| 109. | 谷内一彦、孫立智、李爭艶、飯沼一宇、渡邉建彦。てんかんとヒスタミンレセプターのイメージング。脳の科学。特集「脳機能のイメージング」。227-233、１９９８年 |
| 110. | 谷内一彦、渡辺武、渡邉建彦。ヒスタミン受容体欠損マウス。日本遺伝子治療学会編「遺伝子治療開発研究ハンドブック」。916-919、1999 |
| 111. | 谷内一彦、井上勲、渡辺武、渡邉建彦。ヒスタミンＨ１受容体欠失マウスの行動薬理学。神経研究の進歩。４１（５）784-793、１９９７年。 |
| 112. | 渡邉建彦、谷内一彦。ヒスタミン受容体。生体の科学特集号「受容体」４８（５）376-380、1997年 |
| 113. | 谷内一彦。ポジトロン標識リガンドを用いたヒト神経伝達の画像化：その基礎開発と応用。日本薬理学会雑誌。109:259-269 1997年 |
| 114. | 渡邉建彦、谷内一彦。ヒスタミン受容体：第二世代H1ブロッカーは、何故、非鎮静性か？ 「薬局」４８巻（No. 1)、pp. 39-45、1997年 |
| 115. | 谷内一彦。ヒト脳内ヒスタミンH1受容体のＰＥＴによる解析。特集「中枢ヒスタミン神経系の機能をさぐる」医学のあゆみ １８０巻（２号）。 1997年 pp. 107-111 |
| 116. | 渡邉建彦、福井裕行、谷内一彦。ヒスタミン受容体。「蛋白質・核酸・酵素」増刊号、『脳における情報伝達』４２巻（No. 3) pp. 327-334‚ 1997年 |
| 117. | 谷内一彦、倉増敦朗、渡邉建彦。神経伝達物質と受容体解析法、『神経伝達物質ー受容体の分子機構と病態』、脳と神経科学シリーズ、メジカルビュー社、 p.16-28、1996年 |
| 118. | 渡邉建彦、谷内一彦。神経伝達物質と受容体の神経薬理学、『神経伝達物質ー受容体の分子機構と病態』、脳と神経科学シリーズ、メジカルビュー社、 p.2-14、１９９６年 |
| 119. | 谷内一彦、樋口真人、伊藤正敏、渡邉建彦。 ＰＥＴによる脳機能測定、in vivoレセプターマッピング。ブレイン・サイエンス ７巻 p.155-164（１９９６） |
| 120. | 伊藤正敏、谷内一彦、山口智、藤原竹彦、長沢治夫、横山浩之、飯沼一宇、井戸達雄。ヒト脳神経伝達のＰＥＴによる画像化。脳と発達 ２７：１４６ー１５２（１９９５） |
| 121. | 谷内一彦、渡邉建彦、松澤大樹。ＰＥＴによる測定：ヒスタミン・セロトニン系 脳の神経伝達とレセプターイメージング（小西淳二、館野之男編） 金芳堂 ｐ．１１６ー１３５ （１９９４） |
| 122. | 谷内一彦、渡邉建彦、伊藤正敏。ＰＥＴ／ＳＰＥＣＴによる神経伝達・受容体機能の測定。ＢＭＥ：脳機能の非侵襲的計測 ８、２６ー３５（１９９４） |
| 123. | 谷内一彦、渡邉建彦。ポジトロン（β＋)標識受容体リガンドを用いた神経受容体の画像化。日本薬理学会雑誌１０３：ｐｐ４９−５８（１９９４） |
| 124. | 渡邉建彦、谷内一彦、佐々木雅幸。モノアミン：ヒスタミン作動システム。脳の神経活性物質・受容体アトラス（遠山正弥、高辻功一編）医学書院ｐｐ５４−６３（１９９３） |
| 125. | 谷内一彦、渡邉建彦。ヒスタミンＨ１受容体のＰＥＴによる画像化。代謝２１：眼でみるページ３３５（１９９２） |
| 126. | 谷内一彦、渡邉建彦、伊藤正敏、松澤大樹。ＰＥＴによる神経伝達物質と受容体の研究：神経疾患への応用 神経伝達物質Ｕｐｄａｔｅ：基礎から臨床まで（中村重信編）中外医学社ｐｐ251-258（1991） |
| 127. | 谷内一彦、渡邉建彦、松澤大樹。ＰＥＴによる脳受容体マッピング：ヒスタミンレセプター。日本臨床４９：ｐｐ１２０ー１２５（１９９１） |
| 128. | 谷内一彦、伊藤正敏。ＰＥＴのイメージング：レセプター『脳代謝とその異常』代謝２６：ｐｐ３７７ー３８２（１９８９） |
| 129. | 松澤大樹、谷内一彦、伊藤正敏、畑沢順。ポジトロンエミッションＣＴの現状。『核医学と総合画像診断』新医療ｐｐ１２０−１２３（１９８８） |
| 130. | 谷内一彦、松澤大樹、伊藤正敏、畑沢順。ＰＥＴと脳のレセプター ：老人性痴呆への応用をめざして。老人性痴呆症と脳機能改善薬（朝永正徳、斉藤洋編）、シーエムシー出版ｐｐ９０−９７（１９８８） |
教科書
| 1. | 谷内一彦、渡邉建彦。ヒスタミン受容体（トランスミッター・オータコイドと薬理）『医系薬理学』中外医学社。Pp128-134（1997、2004年改定） |
|---|---|
| 2. | 柳沢輝行、谷内一彦、布木和夫。新薬理学入門。南山堂。1997年（2002年改定） |
| 3. | 日本臨床薬理学会編 臨床薬理学、医学書院 第２版2003年 薬理作用を変化させる基本的因子 pp. 31-35 |
| 4. | 柳澤輝行、飯野正光、丸山敬、三澤美和、谷内一彦ほか。カッツング薬理学（日本語訳）原書第9版 |
| 5. | 柳澤輝行、丸山敬、谷内一彦ほか。イラスト薬理学（日本語訳） 原書2版 |
一般書
| 1. | 松澤大樹、石井慶造、高山豊、畑沢順、福田寛、谷内一彦。目で見る脳とこころ。NHK出版2003.2.25 |
|---|
マスコミでの報道実績
| 朝日新聞 平成22年12月18日（風邪薬半日後も眠る脳） | |
| 読売新聞 平成22年12月19日（抗ヒスタミン薬12時間後の脳内に成分50％） | |
| 読売新聞 平成21年10月14日（市販薬と付き合う：風邪用古いタイプで眠気） | |
| 東京新聞 平成21年2月 1日（花粉症薬の落とし穴） | |
| 共同通信 平成20年1月21日（抗ヒスタミン薬服用によるインペアード・パフォーマンス） | |
| 日本経済新聞 平成18年10月19日（利益相反を超え産学連携を） | |
| 河北新報 平成18年2月22日（東北大学と放医研と連携） | |
| 読売新聞 平成18年2月22日（東北大学と放医研と連携） | |
| 日刊工業 平成18年2月11日（東北大学と放医研と連携） | |
| 毎日新聞 平成17年6月24日（花粉症治療薬×ハンズフリー携帯 ドライバーの反応著しく鈍化） | |
| 読売新聞 令和2年2月8日（花粉症の薬飲み運転、大丈夫？） |
国際的な視点で記載すべき事項（学術交流協定の締結など）
| 1. | 中国浙江大学医学部・客員教授 |
|---|---|
| 2. | 東北大学と放射線医学総合研究所の研究交流協定締結（平成18年2月21日〜現在まで） |
| 3. | メルボルン大学とのアミロイドAβ、タウ、αシヌクレインに関する分子イメージング共同研究 |
| 4. | 日中薬理・臨床薬理ジョイントシンポジウム・オーガナイザー（ウルムチ、平成23年8月7-９日） |
| 5. | JSPS-NRFアジア学術セミナー・日本側責任者（ソウル国立大学、平成24年2月13-17日） |
| 6. | 第87回 日本薬理学会・大会長（仙台市、平成26年3月） |
| 7. | 神経科学分野におけるヨーロッパ‐日本ダブル修士号プログラム |
| 8. | 第４２回 日本臨床薬理学会・大会長（仙台市、令和3年12月予定）「オープンイノベーションを目指して」 |
| 9. | 令和２年４月〜令和４年３月（公社）日本薬理学会理事長 |
